

=> d his nofile

(FILE 'REGISTRY' ENTERED AT 12:42:14 ON 20 AUG 2007)

DEL HIS Y
E THIOURACIL/CN
L1 1 SEA ABB=ON PLU=ON THIOURACIL/CN
L2 STR 141-90-2
L3 70 SEA FAM FUL L2

FILE 'CAPLUS' ENTERED AT 12:43:33 ON 20 AUG 2007

L4 2397 SEA ABB=ON PLU=ON L3
L5 17206 SEA ABB=ON PLU=ON EAR/OBI OR HEARING/OBI
L6 3295 SEA ABB=ON PLU=ON OTO?/OBI
L7 18670 SEA ABB=ON PLU=ON L5 OR L6
L8 2 SEA ABB=ON PLU=ON L7 AND L4
D SCAN
L9 25449 SEA ABB=ON PLU=ON EAR/AB OR (HEAR OR HEARING)/AB
L10 4 SEA ABB=ON PLU=ON L9 AND L4
E EAR DISEASE/CT
E E12+ALL
L11 5888 SEA ABB=ON PLU=ON (DEAF? OR TINNITUS)/BI
L12 1 SEA ABB=ON PLU=ON L4 AND L11
L13 2236 SEA ABB=ON PLU=ON (HYPOACUSIS OR PRESBYCUSIS OR DYSACUSIS OR
HYPERACUSIS OR OTITIS)/BI
L14 1 SEA ABB=ON PLU=ON L4 AND L13
D SCAN
L15 6 SEA ABB=ON PLU=ON L14 OR L12 OR L10 OR L8

FILE 'MEDLINE' ENTERED AT 12:51:06 ON 20 AUG 2007

E EAR DISEASES/CT
E E3+ALL
L16 99503 SEA ABB=ON PLU=ON EAR DISEASES+NT/CT
L17 191347 SEA ABB=ON PLU=ON L16 OR EAR OR HEARING OR OTO?
L18 1675 SEA ABB=ON PLU=ON L1
D TRIAL
E THIOURACIL/CT
E E3+ALL
L19 1675 SEA ABB=ON PLU=ON L18 OR THIOURACIL/CT
L20 6 SEA ABB=ON PLU=ON L19 AND L17
D TRIAL 1
E AMIONGLYCOSIDE ANTIBIOTIC/CT
E ANTIBIOTICS/CT
E E3+AKK
E E3+ALL
E E2+ALL
E AMINOGLYCOSIDES/CT
E E3+ALL
L21 102336 SEA ABB=ON PLU=ON AMINOGLYCOSIDES+NT/CT
L22 17 SEA ABB=ON PLU=ON L21 AND L19
L23 3645 SEA ABB=ON PLU=ON OTOPROTECT? OR OTOTOX?
L24 0 SEA ABB=ON PLU=ON L23 AND L19
L25 114262 SEA ABB=ON PLU=ON ANTINEOPLASTIC AGENTS/CT
L26 0 SEA ABB=ON PLU=ON ANTINEOPLASTIC AGENTS+NT/DCT
L27 682114 SEA ABB=ON PLU=ON ANTINEOPLASTIC AGENTS+NT/CT
L28 88 SEA ABB=ON PLU=ON L19 AND L27
L29 0 SEA ABB=ON PLU=ON L28 AND L16
L30 0 SEA ABB=ON PLU=ON L22 AND L16
L31 9 SEA ABB=ON PLU=ON ZEPP C?/AU

Gregg Polansky 10/712,849

L32 10 SEA ABB=ON PLU=ON HEEFNER D?/AU
 L33 884 SEA ABB=ON PLU=ON RUBIN P?/AU
 L34 230 SEA ABB=ON PLU=ON CURRIE M?/AU
 L35 1131 SEA ABB=ON PLU=ON (L31 OR L32 OR L33 OR L34)
 L36 0 SEA ABB=ON PLU=ON L35 AND L19
 L37 0 SEA ABB=ON PLU=ON L35 AND L16
 L38 8 SEA ABB=ON PLU=ON L35 AND L5

FILE 'CAPLUS' ENTERED AT 13:06:41 ON 20 AUG 2007

L39 67 SEA ABB=ON PLU=ON ZEPP C?/AU
 L40 40 SEA ABB=ON PLU=ON HEEFNER D?/AU
 L41 612 SEA ABB=ON PLU=ON RUBIN P?/AU
 L42 353 SEA ABB=ON PLU=ON CURRIE M?/AU
 L43 1049 SEA ABB=ON PLU=ON (L39 OR L40 OR L41 OR L42)
 L44 1 SEA ABB=ON PLU=ON L43 AND L4
 L45 39597 SEA ABB=ON PLU=ON L11 OR L13 OR L9 OR L6 OR L5
 L46 6 SEA ABB=ON PLU=ON L43 AND L45
 L47 5 SEA ABB=ON PLU=ON L46 NOT L44
 L48 6 SEA ABB=ON PLU=ON L44 OR L15

FILE 'BIOSIS' ENTERED AT 13:10:17 ON 20 AUG 2007

L49 4297 SEA ABB=ON PLU=ON L1 OR THIOURACIL OR THIO URACIL
 L50 36512 SEA ABB=ON PLU=ON HEAR OR HEARING
 L51 2614 SEA ABB=ON PLU=ON OTOPRO? OR OTOTOX?
 L52 76948 SEA ABB=ON PLU=ON EAR
 L53 4 SEA ABB=ON PLU=ON L49 AND L50
 L54 0 SEA ABB=ON PLU=ON L49 AND L51
 L55 10 SEA ABB=ON PLU=ON L49 AND L52
 D SCAN TI L53
 D SCAN TI L55
 L56 13 SEA ABB=ON PLU=ON L55 OR L53
 L57 17 SEA ABB=ON PLU=ON ZEPP C?/AU
 L58 32 SEA ABB=ON PLU=ON HEEFNER D?/AU
 L59 928 SEA ABB=ON PLU=ON RUBIN P?/AU
 L60 355 SEA ABB=ON PLU=ON CURRIE M?/AU
 L61 1324 SEA ABB=ON PLU=ON (L57 OR L58 OR L59 OR L60)
 L62 1 SEA ABB=ON PLU=ON L61 AND (L50 OR L51)
 L63 0 SEA ABB=ON PLU=ON L61 AND L49

FILE 'EMBASE' ENTERED AT 13:19:52 ON 20 AUG 2007

L64 560 SEA ABB=ON PLU=ON L3
 E THIOURACIL/CT
 E E3+ALL
 L65 1197 SEA ABB=ON PLU=ON THIOURACIL/CT OR L64 OR THIOURACIL OR
 MERCAPTOURACIL
 L66 140880 SEA ABB=ON PLU=ON HEAR OR HEARING OR EAR OR OTO? OR OTITIS
 L67 5 SEA ABB=ON PLU=ON L65 AND L66
 L68 20902 SEA ABB=ON PLU=ON (HYPOACUSIS OR PRESBYCUSIS OR DYSACUSIS OR
 HYPERACUSIS OR OTITIS)/BI
 L69 0 SEA ABB=ON PLU=ON L68 AND L64
 L70 62 SEA ABB=ON PLU=ON OTOPROTECT?
 L71 0 SEA ABB=ON PLU=ON L70 AND ?URACIL?

FILE 'BIOSIS' ENTERED AT 13:23:53 ON 20 AUG 2007

L72 12069 SEA ABB=ON PLU=ON (HYPOACUSIS OR PRESBYCUSIS OR DYSACUSIS OR
 HYPERACUSIS OR OTITIS)/BI
 L73 1 SEA ABB=ON PLU=ON L72 AND L49
 L74 5 SEA ABB=ON PLU=ON L73 OR L53

FILE 'EMBASE' ENTERED AT 13:25:32 ON 20 AUG 2007

L75 5 SEA ABB=ON PLU=ON ZEPP C?/AU
 L76 10 SEA ABB=ON PLU=ON HEEFNER D?/AU
 L77 756 SEA ABB=ON PLU=ON RUBIN P?/AU
 L78 206 SEA ABB=ON PLU=ON CURRIE M?/AU
 L79 975 SEA ABB=ON PLU=ON (L75 OR L76 OR L77 OR L78)
 L80 0 SEA ABB=ON PLU=ON L79 AND L65
 L81 12 SEA ABB=ON PLU=ON L66 AND L79

FILE 'WPIX' ENTERED AT 13:27:28 ON 20 AUG 2007

L82 321 SEA ABB=ON PLU=ON THIOURACIL OR MERCAPTLOURACIL OR (MERCAPTO
 OR THIO) (2A) URACIL
 L83 197 SEA ABB=ON PLU=ON DERACIL OR ANTAGOTHYROIL OR NOBILEN OR NSC
 L84 5 SEA ABB=ON PLU=ON HYDROXY (2W) (MERCAPTOPYRIMIDINE OR
 PYRIMIDINETHIOL OR MERCAPTOPYRIMIDINE)
 L85 522 SEA ABB=ON PLU=ON (L82 OR L83 OR L84)
 L86 40192 SEA ABB=ON PLU=ON EAR OR HEAR OR HEARING OR OTO? OR OTITIS
 OR TINNITUS
 L87 1456 SEA ABB=ON PLU=ON (HYPOACUSIS OR PRESBYCUSIS OR DYSACUSIS OR
 HYPERACUSIS OR OTITIS)/BI
 L88 40202 SEA ABB=ON PLU=ON L86 OR L87
 L89 2 SEA ABB=ON PLU=ON L88 AND L85
 L90 57 SEA ABB=ON PLU=ON ZEPP C?/AU
 L91 27 SEA ABB=ON PLU=ON HEEFNER D?/AU
 L92 50 SEA ABB=ON PLU=ON RUBIN P?/AU
 L93 104 SEA ABB=ON PLU=ON CURRIE M?/AU
 L94 217 SEA ABB=ON PLU=ON (L90 OR L91 OR L92 OR L93)
 L95 0 SEA ABB=ON PLU=ON L94 AND L85 L
 L96 8 SEA ABB=ON PLU=ON L94 AND L88

FILE 'CAPLUS, MEDLINE, BIOSIS, EMBASE, WPIX' ENTERED AT 13:35:26 ON 20
 AUG 2007

L97 21 DUP REM L47 L20 L74 L67 L89 (2 DUPLICATES REMOVED)
 ANSWERS '1-5' FROM FILE CAPLUS
 ANSWERS '6-11' FROM FILE MEDLINE
 ANSWERS '12-16' FROM FILE BIOSIS
 ANSWERS '17-19' FROM FILE EMBASE
 ANSWERS '20-21' FROM FILE WPIX
 L98 27 DUP REM L48 L38 L62 L81 L96 (8 DUPLICATES REMOVED)
 ANSWERS '1-6' FROM FILE CAPLUS
 ANSWERS '7-14' FROM FILE MEDLINE
 ANSWERS '15-20' FROM FILE EMBASE
 ANSWERS '21-27' FROM FILE WPIX

FILE 'CAPLUS, MEDLINE, EMBASE' ENTERED AT 13:36:15 ON 20 AUG 2007

L99 22341 SEA ABB=ON PLU=ON PYRIMIDIN? (3A) DERIV?
 L100 284499 SEA ABB=ON PLU=ON EAR OR HEAR OR HEARING OR TINNITIS OR
 OTITIS OR L13
 L101 24 SEA ABB=ON PLU=ON L99 AND L100
 L102 23 DUP REM L101 (1 DUPLICATE REMOVED)
 ANSWERS '1-9' FROM FILE CAPLUS
 ANSWERS '10-11' FROM FILE MEDLINE
 ANSWERS '12-23' FROM FILE EMBASE
 L103 891759 SEA ABB=ON PLU=ON OTOPROTEC? OR PROTECT?
 L104 0 SEA ABB=ON PLU=ON L102 AND L103
 L105 54949 SEA ABB=ON PLU=ON HEARING (2A) LOSS
 L106 2 SEA ABB=ON PLU=ON L105 AND L99
 D SCAN

L107 17784 SEA ABB=ON PLU=ON PYRIMIDINE## (3A) DERIV?
 L108 2 SEA ABB=ON PLU=ON L105 AND L107

=> fil reg

FILE 'REGISTRY' ENTERED AT 13:41:33 ON 20 AUG 2007
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
 COPYRIGHT (C) 2007 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
 provided by InfoChem.

STRUCTURE FILE UPDATES: 19 AUG 2007 HIGHEST RN 944998-48-5
 DICTIONARY FILE UPDATES: 19 AUG 2007 HIGHEST RN 944998-48-5

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 29, 2007


Please note that search-term pricing does apply when
 conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
 predicted properties as well as tags indicating availability of
 experimental property data in the original document. For information
 on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stndoc/properties.html>

=> d que sta l3

L2 STR



NODE ATTRIBUTES:
 DEFAULT MLEVEL IS ATOM
 DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
 RING(S) ARE ISOLATED OR EMBEDDED
 NUMBER OF NODES IS 8

STEREO ATTRIBUTES: NONE
 L3 70 SEA FILE=REGISTRY FAM FUL L2

100.0% PROCESSED 479 ITERATIONS
 SEARCH TIME: 00.00.01

70 ANSWERS

=> _

=> fil reg

FILE 'REGISTRY' ENTERED AT 13:41:42 ON 20 AUG 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2007 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES: 19 AUG 2007 HIGHEST RN 944998-48-5
DICTIONARY FILE UPDATES: 19 AUG 2007 HIGHEST RN 944998-48-5

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 29, 2007


Please note that search-term pricing does apply when
conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document. For information
on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stndoc/properties.html>

=> d que stat l3

L2 STR



NODE ATTRIBUTES:

DEFAULT MLEVEL IS ATOM

DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:

RING(S) ARE ISOLATED OR EMBEDDED

NUMBER OF NODES IS 8

STEREO ATTRIBUTES: NONE

L3 70 SEA FILE=REGISTRY FAM FUL L2

100.0% PROCESSED 479 ITERATIONS

70 ANSWERS

SEARCH TIME: 00.00.01

=> fil caplus medline biosis embase wpix

FILE 'CAPLUS' ENTERED AT 13:41:55 ON 20 AUG 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'MEDLINE' ENTERED AT 13:41:55 ON 20 AUG 2007

FILE 'BIOSIS' ENTERED AT 13:41:55 ON 20 AUG 2007

Copyright (c) 2007 The Thomson Corporation

FILE 'EMBASE' ENTERED AT 13:41:55 ON 20 AUG 2007

Copyright (c) 2007 Elsevier B.V. All rights reserved.

FILE 'WPIX' ENTERED AT 13:41:55 ON 20 AUG 2007

COPYRIGHT (C) 2007 THE THOMSON CORPORATION

=>

=> d que nos 197

```

L1          1 SEA FILE=REGISTRY ABB=ON  PLU=ON  THIOURACIL/CN
L2          STR
L3          70 SEA FILE=REGISTRY FAM FUL L2
L4          2397 SEA FILE=CAPLUS ABB=ON  PLU=ON  L3
L5          17206 SEA FILE=CAPLUS ABB=ON  PLU=ON  EAR/OBI OR HEARING/OBI
L6          3295 SEA FILE=CAPLUS ABB=ON  PLU=ON  OTO?/OBI
L9          25449 SEA FILE=CAPLUS ABB=ON  PLU=ON  EAR/AB OR (HEAR OR HEARING)/AB

L11         5888 SEA FILE=CAPLUS ABB=ON  PLU=ON  (DEAF? OR TINNITUS)/BI
L13         2236 SEA FILE=CAPLUS ABB=ON  PLU=ON  (HYPOACUSIS OR PRESBYCUSIS OR
DYSACUSIS OR HYPERACUSIS OR OTITIS)/BI
L16         99503 SEA FILE=MEDLINE ABB=ON  PLU=ON  EAR DISEASES+NT/CT
L17         191347 SEA FILE=MEDLINE ABB=ON  PLU=ON  L16 OR EAR OR HEARING OR OTO?

L18         1675 SEA FILE=MEDLINE ABB=ON  PLU=ON  L1
L19         1675 SEA FILE=MEDLINE ABB=ON  PLU=ON  L18 OR THIOURACIL/CT
L20         6 SEA FILE=MEDLINE ABB=ON  PLU=ON  L19 AND L17
L39         67 SEA FILE=CAPLUS ABB=ON  PLU=ON  ZEPP C?/AU
L40         40 SEA FILE=CAPLUS ABB=ON  PLU=ON  HEEFNER D?/AU
L41         612 SEA FILE=CAPLUS ABB=ON  PLU=ON  RUBIN P?/AU
L42         353 SEA FILE=CAPLUS ABB=ON  PLU=ON  CURRIE M?/AU
L43         1049 SEA FILE=CAPLUS ABB=ON  PLU=ON  (L39 OR L40 OR L41 OR L42)
L44         1 SEA FILE=CAPLUS ABB=ON  PLU=ON  L43 AND L4
L45         39597 SEA FILE=CAPLUS ABB=ON  PLU=ON  L11 OR L13 OR L9 OR L6 OR L5
L46         6 SEA FILE=CAPLUS ABB=ON  PLU=ON  L43 AND L45
L47         5 SEA FILE=CAPLUS ABB=ON  PLU=ON  L46 NOT L44
L49         4297 SEA FILE=BIOSIS ABB=ON  PLU=ON  L1 OR THIOURACIL OR THIO
URACIL
L50         36512 SEA FILE=BIOSIS ABB=ON  PLU=ON  HEAR OR HEARING
L53         4 SEA FILE=BIOSIS ABB=ON  PLU=ON  L49 AND L50
L64         560 SEA FILE=EMBASE ABB=ON  PLU=ON  L3
L65         1197 SEA FILE=EMBASE ABB=ON  PLU=ON  THIOURACIL/CT OR L64 OR
THIOURACIL OR MERCAPTLOURACIL
L66         140880 SEA FILE=EMBASE ABB=ON  PLU=ON  HEAR OR HEARING OR EAR OR OTO?
OR OTITIS
L67         5 SEA FILE=EMBASE ABB=ON  PLU=ON  L65 AND L66
L72         12069 SEA FILE=BIOSIS ABB=ON  PLU=ON  (HYPOACUSIS OR PRESBYCUSIS OR
DYSACUSIS OR HYPERACUSIS OR OTITIS)/BI
L73         1 SEA FILE=BIOSIS ABB=ON  PLU=ON  L72 AND L49
L74         5 SEA FILE=BIOSIS ABB=ON  PLU=ON  L73 OR L53
L82         321 SEA FILE=WPIX ABB=ON  PLU=ON  THIOURACIL OR MERCAPTLOURACIL OR
(MERCAPTO OR THIO) (2A) URACIL
L83         197 SEA FILE=WPIX ABB=ON  PLU=ON  DERACIL OR ANTAGOTHYROI OR
NOBILEN OR NSC
L84         5 SEA FILE=WPIX ABB=ON  PLU=ON  HYDROXY (2W) (MERCAPTOPYRIMIDINE
OR PYRIMIDINETHIOL OR MERCAPTOPYRIMIDINE)

```

Gregg Polansky 10/712,849

L85 522 SEA FILE=WPIX ABB=ON PLU=ON (L82 OR L83 OR L84)
L86 40192 SEA FILE=WPIX ABB=ON PLU=ON EAR OR HEAR OR HEARING OR OTO?
OR OTITIS OR TINNITUS
L87 1456 SEA FILE=WPIX ABB=ON PLU=ON (HYPOACUSIS OR PRESBYCUSIS OR
DYSACUSIS OR HYPERACUSIS OR OTITIS)/BI
L88 40202 SEA FILE=WPIX ABB=ON PLU=ON L86 OR L87
L89 2 SEA FILE=WPIX ABB=ON PLU=ON L88 AND L85
L97 21 DUP REM L47 L20 L74 L67 L89 (2 DUPLICATES REMOVED)

=> d que nos 198

L2 STR
L3 70 SEA FILE=REGISTRY FAM FUL L2
L4 2397 SEA FILE=CAPLUS ABB=ON PLU=ON L3
L5 17206 SEA FILE=CAPLUS ABB=ON PLU=ON EAR/OBI OR HEARING/OBI
L6 3295 SEA FILE=CAPLUS ABB=ON PLU=ON OTO?/OBI
L7 18670 SEA FILE=CAPLUS ABB=ON PLU=ON L5 OR L6
L8 2 SEA FILE=CAPLUS ABB=ON PLU=ON L7 AND L4
L9 25449 SEA FILE=CAPLUS ABB=ON PLU=ON EAR/AB OR (HEAR OR HEARING)/AB

L10 4 SEA FILE=CAPLUS ABB=ON PLU=ON L9 AND L4
L11 5888 SEA FILE=CAPLUS ABB=ON PLU=ON (DEAF? OR TINNITUS)/BI
L12 1 SEA FILE=CAPLUS ABB=ON PLU=ON L4 AND L11
L13 2236 SEA FILE=CAPLUS ABB=ON PLU=ON (HYPOACUSIS OR PRESBYCUSIS OR
DYSACUSIS OR HYPERACUSIS OR OTITIS)/BI
L14 1 SEA FILE=CAPLUS ABB=ON PLU=ON L4 AND L13
L15 6 SEA FILE=CAPLUS ABB=ON PLU=ON L14 OR L12 OR L10 OR L8
L31 9 SEA FILE=MEDLINE ABB=ON PLU=ON ZEPP C?/AU
L32 10 SEA FILE=MEDLINE ABB=ON PLU=ON HEEFNER D?/AU
L33 884 SEA FILE=MEDLINE ABB=ON PLU=ON RUBIN P?/AU
L34 230 SEA FILE=MEDLINE ABB=ON PLU=ON CURRIE M?/AU
L35 1131 SEA FILE=MEDLINE ABB=ON PLU=ON (L31 OR L32 OR L33 OR L34)
L38 8 SEA FILE=MEDLINE ABB=ON PLU=ON L35 AND L5
L39 67 SEA FILE=CAPLUS ABB=ON PLU=ON ZEPP C?/AU
L40 40 SEA FILE=CAPLUS ABB=ON PLU=ON HEEFNER D?/AU
L41 612 SEA FILE=CAPLUS ABB=ON PLU=ON RUBIN P?/AU
L42 353 SEA FILE=CAPLUS ABB=ON PLU=ON CURRIE M?/AU
L43 1049 SEA FILE=CAPLUS ABB=ON PLU=ON (L39 OR L40 OR L41 OR L42)
L44 1 SEA FILE=CAPLUS ABB=ON PLU=ON L43 AND L4
L48 6 SEA FILE=CAPLUS ABB=ON PLU=ON L44 OR L15
L50 36512 SEA FILE=BIOSIS ABB=ON PLU=ON HEAR OR HEARING
L51 2614 SEA FILE=BIOSIS ABB=ON PLU=ON OTOPRO? OR OTOTOX?
L57 17 SEA FILE=BIOSIS ABB=ON PLU=ON ZEPP C?/AU
L58 32 SEA FILE=BIOSIS ABB=ON PLU=ON HEEFNER D?/AU
L59 928 SEA FILE=BIOSIS ABB=ON PLU=ON RUBIN P?/AU
L60 355 SEA FILE=BIOSIS ABB=ON PLU=ON CURRIE M?/AU
L61 1324 SEA FILE=BIOSIS ABB=ON PLU=ON (L57 OR L58 OR L59 OR L60)
L62 1 SEA FILE=BIOSIS ABB=ON PLU=ON L61 AND (L50 OR L51)
L66 140880 SEA FILE=EMBASE ABB=ON PLU=ON HEAR OR HEARING OR EAR OR OTO?
OR OTITIS
L75 5 SEA FILE=EMBASE ABB=ON PLU=ON ZEPP C?/AU
L76 10 SEA FILE=EMBASE ABB=ON PLU=ON HEEFNER D?/AU
L77 756 SEA FILE=EMBASE ABB=ON PLU=ON RUBIN P?/AU
L78 206 SEA FILE=EMBASE ABB=ON PLU=ON CURRIE M?/AU
L79 975 SEA FILE=EMBASE ABB=ON PLU=ON (L75 OR L76 OR L77 OR L78)
L81 12 SEA FILE=EMBASE ABB=ON PLU=ON L66 AND L79
L86 40192 SEA FILE=WPIX ABB=ON PLU=ON EAR OR HEAR OR HEARING OR OTO?
OR OTITIS OR TINNITUS
L87 1456 SEA FILE=WPIX ABB=ON PLU=ON (HYPOACUSIS OR PRESBYCUSIS OR
DYSACUSIS OR HYPERACUSIS OR OTITIS)/BI

Gregg Polansky 10/712,849

L88 40202 SEA FILE=WPIX ABB=ON PLU=ON L86 OR L87
 L90 57 SEA FILE=WPIX ABB=ON PLU=ON ZEPP C?/AU
 L91 27 SEA FILE=WPIX ABB=ON PLU=ON HEEFNER D?/AU
 L92 50 SEA FILE=WPIX ABB=ON PLU=ON RUBIN P?/AU
 L93 104 SEA FILE=WPIX ABB=ON PLU=ON CURRIE M?/AU
 L94 217 SEA FILE=WPIX ABB=ON PLU=ON (L90 OR L91 OR L92 OR L93)
 L96 8 SEA FILE=WPIX ABB=ON PLU=ON L94 AND L88
 L98 27 DUP REM L48 L38 L62 L81 L96 (8 DUPLICATES REMOVED)

=> d .ca hitstr 197 1-5; d ibib ab ct 187 6-21; d ibib 198 1-27

L97 ANSWER 1 OF 21 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 2006:1311249 CAPLUS Full-text
 DOCUMENT NUMBER: 146:55519
 TITLE: Bacterial enterotoxin ST peptide variants that
 activate the guanylate cyclase C receptor and their
 use for the treatment of gastrointestinal disorders
 INVENTOR(S): Currie, Mark G.; Mahajan-Miklos, Shalina
 PATENT ASSIGNEE(S): USA
 SOURCE: U.S. Pat. Appl. Publ., 103pp., Cont.-in-part of U.S.
 Ser. No. 796,719.
 CODEN: USXXCO
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 5
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2006281682	A1	20061214	US 2004-845895	20040514
US 2004266989	A1	20041230	US 2004-766735	20040128
US 2005020811	A1	20050127	US 2004-796719	20040309
US 2006258593	A1	20061116	US 2004-899806	20040727
AU 2005222387	A1	20050922	AU 2005-222387	20050308
CA 2558050	A1	20050922	CA 2005-2558050	20050308
WO 2005087797	A1	20050922	WO 2005-US7752	20050308
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
EP 1730172	A1	20061213	EP 2005-732019	20050308
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR				
CN 101010335	A	20070801	CN 2005-80014557	20050308
NO 2006004121	A	20061122	NO 2006-4121	20060913
PRIORITY APPLN. INFO.:				
			US 2003-443098P	P 20030128
			US 2003-471288P	P 20030515
			US 2003-519460P	P 20031112
			US 2004-766735	A2 20040128
			US 2004-796719	A2 20040309
			US 2004-845895	A2 20040514
			US 2004-899806	A 20040727

US 2005-54071
WO 2005-US7752A 20050208
W 20050308

OTHER SOURCE(S): MARPAT 146:55519

ED Entered STN: 15 Dec 2006

AB Peptides and other agents that activate the guanylate cyclase C (GC-C) receptor are provided for treating irritable bowel syndrome (IBS) and other gastrointestinal disorders and conditions (e.g., gastrointestinal motility disorders, functional gastrointestinal disorders, gastroesophageal reflux disease (GERD), duodenogastric reflux, Crohn's disease, ulcerative colitis, inflammatory bowel disease, functional heartburn, dyspepsia (including functional dyspepsia or non-ulcer dyspepsia), gastroparesis, chronic intestinal pseudo-obstruction (or colonic pseudo-obstruction)), and disorders and conditions associated with constipation (e.g., constipation associated with use of opiate pain killers, post-surgical constipation (post-operative ileus), and constipation associated with neuropathic disorders), as well as other conditions and disorders. The peptides, like the bacterial ST peptides, have six Cys residues which form 3 disulfide bonds in the mature and active form of the peptide. In particular, variant ST peptides (CCEYCSNPACTGCY and NSSNYCCEYCCNPACTGCY), and the wild-type ST peptide (NSSNYCCELCNPACTGCY) are produced recombinantly or synthetically and tested in animal models. The peptides bind to the intestinal GC-C receptor, a key regulator of fluid and electrolyte balance in the intestine. When stimulated, this receptor, which is located on the apical membrane of the intestinal epithelial surface, causes an increase in intestinal epithelial cGMP. This increase in cGMP is believed to cause an increase in Cl⁻ and K⁺ secretion, leading to changes in intestinal fluid and electrolyte transport and increased intestinal motility.

INCL 514013000; 530326000; 514015000; 514014000; 514282000; 514317000;
514355000; 514454000; 514618000

CC 1-9 (Pharmacology)

IT Ear

(inner, disorders; bacterial enterotoxin ST peptide variants activating guanylate cyclase C receptor useful in treatment of gastrointestinal disorders)

L97 ANSWER 2 OF 21 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2005:78296 CAPLUS Full-text

DOCUMENT NUMBER: 142:170088

TITLE: Methods for the treatment of gastrointestinal disorders using guanylate cyclase C receptor activators, such as ST peptide variants

INVENTOR(S): Currie, Mark G.; Mahajan-Miklos, Shalina

PATENT ASSIGNEE(S): USA

SOURCE: U.S. Pat. Appl. Publ., 83 pp., Cont.-in-part of U.S. Ser. No. 766,735.

CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 5

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2005020811	A1	20050127	US 2004-796719	20040309
US 2004266989	A1	20041230	US 2004-766735	20040128
US 2006281682	A1	20061214	US 2004-845895	20040514
US 2006258593	A1	20061116	US 2004-899806	20040727
AU 2005222387	A1	20050922	AU 2005-222387	20050308
CA 2558050	A1	20050922	CA 2005-2558050	20050308
WO 2005087797	A1	20050922	WO 2005-US7752	20050308

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,

Gregg Polansky 10/712,849

CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
 RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

EP 1730172 A1 20061213 EP 2005-732019 20050308
 R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR

CN 101010335 A 20070801 CN 2005-80014557 20050308
 IN 2006DN05053 A 20070810 IN 2006-DN5053 20060901
 NO 2006004121 A 20061122 NO 2006-4121 20060913

PRIORITY APPLN. INFO.:

US 2003-443098P P 20030128
 US 2003-471288P P 20030515
 US 2003-519460P P 20031112
 US 2004-766735 A2 20040128
 US 2004-796719 A2 20040309
 US 2004-845895 A2 20040514
 US 2004-899806 A 20040727
 US 2005-54071 A 20050208
 WO 2005-US7752 W 20050308

OTHER SOURCE(S): MARPAT 142:170088

ED Entered STN: 28 Jan 2005

AB The present invention features compns. and related methods for treating irritable bowel syndrome (IBS) and other gastrointestinal disorders and conditions using peptides and other agents that activate the guanylate cyclase C (GC-C) receptor. The gastrointestinal disorders include gastrointestinal motility disorders, functional gastrointestinal disorders, gastro-esophageal reflux disease (GERD), Crohn's disease, ulcerative colitis, inflammatory bowel disease, functional heartburn, dyspepsia (including functional dyspepsia or nonulcer dyspepsia), gastro-paresis, chronic intestinal pseudo-obstruction (or colonic pseudo-obstruction), and disorders and conditions associated with constipation, e.g., constipation associated with use of opiate pain killers, post-surgical constipation, and constipation associated with neuropathic disorders as well as other conditions and disorders. Provided are sequences of the peptides of the invention, as well as a method for their preparation. The peptides of the invention, like the bacterial ST peptides, have six Cys residues. These six Cys residues form three disulfide bonds in the mature and active form of the peptide. If the six Cys residues are identified, from the amino to carboxy terminus of the peptide, as A, B, C, D, E, and F, then the disulfide bonds form as follows: A-D, B-E, and C-F. The formation of these bonds is thought to be important for GC-C receptor binding. Certain of the peptides of the invention include a potentially functional chymotrypsin cleavage site. Cleavage at chymotrypsin cleavage site reduces or eliminates the ability of the peptide to bind to the GC-C receptor. It is expected that chymotrypsin cleavage will moderate the action of a peptide of the invention having an appropriately positioned chymotrypsin cleavage site as the peptide passes through the intestinal tract.

IC ICM C07K007-08

ICS C07K007-06

INCL 530327000; 530328000

CC 1-9 (Pharmacology)

IT Ear

(inner, disorder; methods for treatment of gastrointestinal disorders using guanylate cyclase C (GC-C) receptor activators, such as ST peptide variants)

L97 ANSWER 3 OF 21 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 2004:681510 CAPLUS Full-text
 DOCUMENT NUMBER: 141:200192
 TITLE: Methods and compositions using guanylate cyclase C
 receptor activators for the treatment of
 gastrointestinal disorders
 INVENTOR(S): Currie, Mark G.; Mahajan-Miklos, Shalina
 PATENT ASSIGNEE(S): Microbia, Inc., USA
 SOURCE: PCT Int. Appl., 93 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 5
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004069165	A2	20040819	WO 2004-US2390	20040128
WO 2004069165	A3	20050317		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI			
RW:	BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
AU 2004210161	A1	20040819	AU 2004-210161	20040128
CA 2514507	A1	20040819	CA 2004-2514507	20040128
EP 1594517	A2	20051116	EP 2004-706011	20040128
EP 1594517	B1	20070620		
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK			
BR 2004007071	A	20060124	BR 2004-7071	20040128
CN 1795007	A	20060628	CN 2004-80008533	20040128
JP 2006516631	T	20060706	JP 2006-503109	20040128
AT 365174	T	20070715	AT 2004-706011	20040128
MX 2005PA08097	A	20060208	MX 2005-PA8097	20050728
IN 2005DN03394	A	20070601	IN 2005-DN3394	20050801
NO 2005003864	A	20051026	NO 2005-3864	20050818
PRIORITY APPLN. INFO.:			US 2003-443098P	P 20030128
			US 2003-471288P	P 20030515
			US 2003-519460P	P 20031112
			WO 2004-US2390	W 20040128

OTHER SOURCE(S): MARPAT 141:200192

ED Entered STN: 20 Aug 2004

AB The invention discloses compns. and related methods for treating irritable bowel syndrome (IBS) and other gastrointestinal disorders and conditions, e.g. gastrointestinal motility disorders, functional gastrointestinal disorders, gastroesophageal reflux disease (GERD), Crohn's disease, ulcerative colitis, inflammatory bowel disease, functional heartburn, dyspepsia (including functional dyspepsia or nonulcer dyspepsia), gastroparesis, chronic intestinal pseudo-obstruction (or colonic pseudo-obstruction), and disorders and conditions associated with constipation, e.g., constipation associated with use of opiate pain killers, post-surgical constipation, and constipation associated with neuropathic disorders as well as other conditions and disorders using peptides and other agents that activate the guanylate cyclase C (GC-C) receptor.

IC ICM A61K

CC 1-9 (Pharmacology)

IT Ear

(inner, disorder; guanylate cyclase C receptor activators for treatment of gastrointestinal disorders)

L97 ANSWER 4 OF 21 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2003:82239 CAPLUS Full-text

DOCUMENT NUMBER: 138:163170

TITLE: The safety of 6-mercaptopurine for childbearing patients with inflammatory bowel disease: A retrospective cohort study

AUTHOR(S): Francella, Andrew; Dyan, Alan; Bodian, Carol; Rubin, Peter; Chapman, Mark; Present, Daniel H.

CORPORATE SOURCE: Department of Medicine and Biostatistics, Mount Sinai Hospital Medical Center, New York, NY, USA-

SOURCE: Gastroenterology (2003), 124(1), 9-17

CODEN: GASTAB; ISSN: 0016-5085

PUBLISHER: W. B. Saunders Co.

DOCUMENT TYPE: Journal

LANGUAGE: English

ED Entered STN: 03 Feb 2003

AB 6-Mercaptopurine/azathioprine is effective in IBD patients. However, data regarding toxicity associated with pregnancy are lacking, raising both patients' and physicians' concerns and sometimes resulting in elective abortion. To evaluate potential toxicity of 6-mercaptopurine (6-MP), we reviewed the records of 485 patients who had received the drug. We contacted 462, of whom 155 had conceived at least 1 pregnancy after developing IBD. Pregnancies were analyzed as to whether the patient had taken 6-MP before, or at the time of, conception. These were compared with IBD patients who had their pregnancies before taking 6-MP. We collected data on live births, spontaneous abortions, prematurity, abortions secondary to birth defects, major and minor congenital birth defects, infections, and neoplasia. Outcomes were analyzed comparing pregnancies from men and women who had taken or were currently taking 6-MP to controls. There was no statistical difference in conception failures (defined as a spontaneous abortion), abortion secondary to a birth defect, major congenital malformations, neoplasia, or increased infections among male or female patients taking 6-MP compared with controls (RR = 0.85 [0.47-1.55], P = 0.59). 6-MP use before or at conception or during pregnancy appears to be safe. Discontinuation of the drug before and during pregnancy is not indicated.

CC 1-7 (Pharmacology)

IT Ear, disease

Inflammation

(otitis media, infant infection; 6-mercaptopurine effect on pregnancy outcome in male and female patients with inflammatory bowel disease)

REFERENCE COUNT: 52 THERE ARE 52 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L97 ANSWER 5 OF 21 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2000:627982 CAPLUS Full-text

DOCUMENT NUMBER: 133:213188

TITLE: Compositions for the treatment of neuropathic pain, tinnitus, and other disorders with R-(-)-ketoprofen

INVENTOR(S): Jerussi, Thomas P.; Rubin, Paul D.

PATENT ASSIGNEE(S): Sepracor Inc., USA

SOURCE: PCT Int. Appl., 26 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000051595	A1	20000908	WO 2000-US5170	20000301
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
US 6362227	B1	20020326	US 2000-507470	20000222
CA 2362489	A1	20000908	CA 2000-2362489	20000301
EP 1156794	A1	20011128	EP 2000-915921	20000301
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
JP 2003520193	T	20030702	JP 2000-602063	20000301
US 2002147238	A1	20021010	US 2002-62766	20020205
US 6620851	B2	20030916		
US 2004019111	A1	20040129	US 2003-620704	20030717
PRIORITY APPLN. INFO.:			US 1999-122382P	P 19990302
			US 2000-507470	A 20000222
			WO 2000-US5170	W 20000301
			US 2002-62766	A3 20020205

ED Entered STN: 10 Sep 2000

AB Methods of treating neuropathic pain, tinnitus, and related disorders are disclosed. These methods comprise the administration of optically pure R(-)-ketoprofen compns. Tablets contained R(-)-ketoprofen 20, lactose 134.5, starch 30, pregelatinized corn starch 15, and Mg stearate 0.5 g.

IC ICM A61K031-19

CC 63-6 (Pharmaceuticals)

Section cross-reference(s): 1

ST ketoprofen enantiomer neuropathic pain; tinnitus ketoprofen enantiomer

IT Nervous system

(Guillain-Barre syndrome; compns. for treatment of neuropathic pain and tinnitus with R(-)-ketoprofen)

IT Antibiotics

(aminoglycoside; compns. for treatment of neuropathic pain and tinnitus with R(-)-ketoprofen)

IT Brain

(cerebellum, disease; compns. for treatment of neuropathic pain and tinnitus with R(-)-ketoprofen)

IT Movement disorders

(cerebral palsy; compns. for treatment of neuropathic pain and tinnitus with R(-)-ketoprofen)

IT Analgesics

Anemia (disease)

Aneurysm

Arteriosclerosis

Cardiovascular agents

Diuretics

Hypertension

Hypothyroidism

Meningitis

Syphilis

(compns. for treatment of neuropathic pain and tinnitus with R-(-)-ketoprofen)

IT Heavy metals

RL: ADV (Adverse effect, including toxicity); BIOL (Biological study)
(compns. for treatment of neuropathic pain and tinnitus with R-(-)-ketoprofen)

IT Cardiovascular system

Spinal cord

(disease; compns. for treatment of neuropathic pain and tinnitus with R-(-)-ketoprofen)

IT Ear

(inner, labyrinthitis; compns. for treatment of neuropathic pain and tinnitus with R-(-)-ketoprofen)

IT Nerve, disease

(neuropathy, pain from; compns. for treatment of neuropathic pain and tinnitus with R-(-)-ketoprofen)

IT Ear

(otitis; compns. for treatment of neuropathic pain and tinnitus with R-(-)-ketoprofen)

IT Nerve, disease

(peripheral, injury; compns. for treatment of neuropathic pain and tinnitus with R-(-)-ketoprofen)

IT Brain

(stem, disease; compns. for treatment of neuropathic pain and tinnitus with R-(-)-ketoprofen)

IT Drug delivery systems

(tablets; compns. for treatment of neuropathic pain and tinnitus with R-(-)-ketoprofen)

IT Brain

(thalamus, disease; compns. for treatment of neuropathic pain and tinnitus with R-(-)-ketoprofen)

IT Ear

(tinnitus; compns. for treatment of neuropathic pain and tinnitus with R-(-)-ketoprofen)

IT Injury

(trauma; compns. for treatment of neuropathic pain and tinnitus with R-(-)-ketoprofen)

IT 63-36-5D, Salicylate, derivs., biological studies 130-95-0, Quinine
630-08-0, Carbon monoxide, biological studies

RL: ADV (Adverse effect, including toxicity); BIOL (Biological study)
(compns. for treatment of neuropathic pain and tinnitus with R-(-)-ketoprofen)

IT 56105-81-8, (-)-Ketoprofen 56105-81-8D, (-)-Ketoprofen, salts or solvates

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(compns. for treatment of neuropathic pain and tinnitus with R-(-)-ketoprofen)

REFERENCE COUNT: 11 THERE ARE 11 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

Gregg Polansky 10/712,849

DOC. NO. CPI: C2007-186592 [49]
 TITLE: New Streptococcus pneumoniae immunogenic composition
 comprises capsular saccharides from different S.
 pneumoniae serotypes, useful for treating or preventing
 S. pneumoniae infection, e.g. pneumonia or otitis
 media
 DERWENT CLASS: B04; D16
 INVENTOR: BIEMANS R L; GARCON N M; HERMAND P V; POOLMAN J; VAN
 MECHELEN M P
 PATENT ASSIGNEE: (GLAX-C) GLAXOSMITHKLINE BIOLOGICALS SA
 COUNTRY COUNT: 116

PATENT INFO ABBR.:

PATENT NO	KIND	DATE	WEEK	LA	PG	MAIN IPC
WO 2007071707	A2	20070628	(200749)*	EN	91	[10]

APPLICATION DETAILS:

PATENT NO	KIND	APPLICATION	DATE
WO 2007071707	A2	WO 2006-EP69974	20061220

PRIORITY APPLN. INFO: WO 2006-GB4634 20061212
 GB 2005-26232 20051222
 GB 2006-7087 20060407
 GB 2006-7088 20060407
 GB 2006-9902 20060518
 GB 2006-20336 20061012
 GB 2006-20337 20061012
 GB 2006-20815 20061019
 GB 2006-20816 20061019

AB WO 2007071707 A2 UPAB: 20070801

NOVELTY - A S. pneumoniae immunogenic composition comprising 9-14 or more capsular saccharides from different S. pneumoniae serotypes conjugated to 2 or more different carrier proteins, where the composition comprises serotype 19F capsular saccharide conjugated to Diphtheria toxoid (DT) or CRM197, where 19F is the only saccharide in the composition conjugated to diphtheria toxoid DT or CRM197, is new.

DETAILED DESCRIPTION - INDEPENDENT CLAIMS are included for: (1) a vaccine kit comprising the immunogenic composition and further comprising for concomitant or sequential administration an adjuvant;

(2) a vaccine comprising the immunogenic composition and a pharmaceutical excipient;

(3) a process for making the vaccine comprising mixing the immunogenic composition with a pharmaceutical excipient; (4) a method of immunizing a human host against disease caused by S. pneumoniae infection;

(5) a method of eliciting a protective immune response in infants against otitis media; and

(6) a method of eliciting a protective immune response to infants or elderly against S. pneumoniae.

ACTIVITY - Antibacterial; Antiinflammatory; Respiratory-Gen; Auditory; Neuroprotective; Ophthalmological. No biological data given.

MECHANISM OF ACTION - Vaccine.

USE - The immunogenic composition or vaccine is useful for the treatment or prevention of disease caused by S. pneumoniae infection, or in the manufacture of a medicament for the treatment or prevention of diseases caused by S. pneumoniae infection. The disease is pneumonia, invasive pneumococcal disease (IPD), or chronic obstructive pulmonary disease (COPD) of elderly humans. The

disease is otitis media, meningitis and/or bacteremia, or conjunctivitis of infant humans (all claimed).

L87 ANSWER 7 OF 1456 WPIX COPYRIGHT 2007 THE THOMSON CORP on STN
 ACCESSION NUMBER: 2007-504805 [49] WPIX
 CROSS REFERENCE: 2005-194991; 2005-532171; 2007-342309
 DOC. NO. CPI: C2007-185438 [49]
 TITLE: Treating otitis externa in a human patient
 comprises topically administering liquid ear drop
 composition to Aspergillus-affected external ear canal of
 human patient
 DERWENT CLASS: B05; C03
 INVENTOR: LANE E M
 PATENT ASSIGNEE: (FAIR-N) FAIRFIELD CLINICAL TRIALS LLC
 COUNTRY COUNT: 1

PATENT INFO ABBR.:

PATENT NO	KIND	DATE	WEEK	LA	PG	MAIN IPC
US 20070078116	A1	20070405	(200749)*	EN	11[4]	

APPLICATION DETAILS:

PATENT NO	KIND	APPLICATION	DATE
US 20070078116	A1 Provisional	US 2003-496409P	20030820
US 20070078116	A1 Provisional	US 2003-505754P	20030926
US 20070078116	A1 CIP of	US 2004-771330	20040205
US 20070078116	A1	US 2006-543203	20061005

PRIORITY APPLN. INFO: US 2006-543203 20061005
 US 2003-496409P 20030820
 US 2003-505754P 20030926
 US 2004-771330 20040205

AB US 20070078116 A1 UPAB: 20070801
 NOVELTY - Treating otitis externa in a human patient comprises topically administering liquid ear drop composition to the Aspergillus-affected external ear canal of human patient. The liquid ear drop composition comprises antifungal, a corticosteroid anti-inflammatory agent and an acidifying agent. The otitis externa is caused by Aspergillus species.
 ACTIVITY - Auditory.
 Itraconazole (1%) solution in a vehicle containing glacial acetic acid (2%), hydrocortisone (1%), benzalkonium chloride (0.02%), sodium acetate trihydrate (0.015%), and citric acid (0.2%) in propylene glycol or vehicle alone was administered four (4) drops in the affected ear twice daily for 10 days to patients diagnosed with otitis externa. Six out of the seven patients receiving the 1% Itraconazole solution were cured, with the ear canal drying up within 3-5 days; symptom relief was achieved by 3-5 days with complete remission of disease seen at 12-15 days (cure). These patients remained disease free at 18-21 days. Vehicle alone was ineffective at curing fungal otitis externa in all but one case.
 MECHANISM OF ACTION - None given.
 USE - The method is useful for treating otitis externa in human patient.
 ADVANTAGE - The composition decreases the incidence of candidiasis in patient undergoing bone marrow transplantation who receives cytotoxic chemotherapy and/or radiation therapy.

L87 ANSWER 8 OF 1456 WPIX COPYRIGHT 2007 THE THOMSON CORP on STN
 ACCESSION NUMBER: 2007-496087 [48] WPIX
 DOC. NO. CPI: C2007-182781 [48]
 TITLE: New dihydropseudo erythromycin derivative, useful for
 prevention-treatment of inflammatory disease e.g.
 inflammatory bowel disease, Crohn's disease, ulcerative
 colitis, chronic obstructive pulmonary disease or
 sinusitis
 DERWENT CLASS: B02
 INVENTOR: NAGAI K; OMURA S; SHIMA H; SUNAZUKA T; YAMABE H
 PATENT ASSIGNEE: (KITA-C) KITASATO INST; (APHO-N) APHOENIX INC
 COUNTRY COUNT: 115

PATENT INFO ABBR.:

PATENT NO	KIND	DATE	WEEK	LA	PG	MAIN IPC
WO 2007043710	A1	20070419	(200748)*	JA	100[0]	

APPLICATION DETAILS:

PATENT NO	KIND	APPLICATION	DATE
WO 2007043710	A1	WO 2006-JP320888	20061013

PRIORITY APPLN. INFO: JP 2005-301070 20051014

AB WO 2007043710 A1 UPAB: 20070727

NOVELTY - Dihydropseudo erythromycin derivative (I) or its salt is new.
 DETAILED DESCRIPTION - Dihydropseudo erythromycin derivative of formula (I) or
 its salt is new.

Me=methyl;

R1,R2=H, alkyl, acyl, sulfonyl, (un)substituted aryl substituted alkyl, aryl
 substituted alkyl oxycarbonyl, alkenyl or alkynyl, or R1 and R2 combine with
 adjoining nitrogen atom to form optionally substituted alicyclic heterocyclic
 group;

R3=H, optionally substituted acyl or aryl substituted alkyl oxycarbonyl;

A=H;

B=hydroxyl or group of formula (II), or A and B combine to form =O; R4=H or
 acyl;

R=group of formula (III) or (V), or Me-C(=D)-; R5,R6=H or acyl, or R5 and R6
 combine to form carbonyl or optionally substituted alkylene; and D=O, H, OH or
 N-OH.

An INDEPENDENT CLAIM is included for commercial package containing the
 documents, describing that the preventive-therapeutic agent of inflammatory
 disease contains the compound (I) or its salt as an active ingredient, and the
 agent is used for the prevention-treatment of inflammatory disease.

ACTIVITY - Antiinflammatory; Gastrointestinal-Gen.; Antiulcer; Respiratory-
 Gen.; CNS-Gen.; Auditory; Antipsoriatic; Uropathic. Trinitro benzene sulfonic-
 acid (TNBS) solution was injected into rectum of 8 weeks old SD type male rats
 under pentobarbital anesthesia and colitis model was produced. Fecal-occult-
 blood score was measured after two days of TNBS administration. De(3'-
 dimethylamino)-3'-morpholino-9- dihydro-pseudoerythromycin A 6,9-epoxide (Ia)
 was administered orally to the animal model twice a day for six days. Large
 intestine was extracted, the grade of damage was scored according to method
 specified in Wallace, J.L et al, Inhibition of leukotriene synthesis markedly
 accelerates healing in a rat model of inflammatory bowel disease,
 Gastroenterology 96,29 36 (1989), and drug efficacy was evaluated. (Ia)
 Exhibited an ulcer inflammation score of 2.93plus minus0.41 in rats in a TNBS
 induced colitis assay. (Ia) Had excellent TNBS induced large intestine-ulcer
 improving effect.

MECHANISM OF ACTION - None given.

USE - For manufacturing pharmaceutical for prevention-treatment of inflammatory disease e.g. inflammatory bowel disease (claimed) such as Crohn's disease, ulcerative colitis, chronic obstructive pulmonary disease, chronic bronchitis, respiratory-disease, cystic fibrosis, diffuse panbronchiolitis, pneumonia, lung fibrosis, sinusitis, bronchiectasis, paranasal-sinuses bronchial syndrome, interstitial pneumonia, otitis-media-with-effusion (exudative otitis media), psoriasis, frequent urination (pollakiuria) and interstitial cystitis.

ADVANTAGE - The new dihydropseudo erythromycin derivative has excellent stability with respect to acid and excellent antiinflammatory activity.

L87 ANSWER 9 OF 1456 WPIX COPYRIGHT 2007 THE THOMSON CORP on STN
 ACCESSION NUMBER: 2007-495632 [48] WPIX
 DOC. NO. CPI: C2007-182653 [48]
 TITLE: Treating or preventing a middle ear infection e.g. otitis media involves transmembrane administration of a carrier composition comprising a medicament and a non-ionic surfactant to the tympanic membrane
 DERWENT CLASS: A96; B02
 INVENTOR: CAMPBELL W R; JOHNSON R H; PAULSEN N E
 PATENT ASSIGNEE: (PIED-N) PIEDMONT PHARM LLC
 COUNTRY COUNT: 115

PATENT INFO ABBR.:

PATENT NO	KIND	DATE	WEEK	LA	PG	MAIN IPC
WO 2007037886	A2	20070405	(200748)*	EN	13[0]	

APPLICATION DETAILS:

PATENT NO	KIND	APPLICATION	DATE
WO 2007037886	A2	WO 2006-US33598	20060825

PRIORITY APPLN. INFO: US 2005-720536P 20050926

AB WO 2007037886 A2 UPAB: 20070727

NOVELTY - Treating or preventing a middle ear infection involves applying a transmembrane carrier composition comprising a medicament, to the outer surface of the tympanic membrane.

ACTIVITY - Auditory; Analgesic; Antiinflammatory. A transmembrane carrier composition comprising: ciprofloxacin hydrochloride, monohydrate dexamethasone alcohol, hydroxyethyl cellulose, benzalkonium chloride, sodium acetate, (trihydrate) acetic acid, sodium chloride, ethylene diamine tetra acetic acid, tyloxapol, glycerin, boric acid, sodium hydroxide/hydrochloric acid and purified water was administered orally (2 - 6 drops) twice per day for 6 days, approximately 8 hours apart, by gavage to chinchillas suffering from middle ear infection, while a second group of chinchillas did not receive anything (control). The animals were then examined. The results showed the number of ears infected/total number ears was 7/10 for control group while no infection was observed in test group. This demonstrates the efficacy of the composition in treating middle ear infection

MECHANISM OF ACTION - None given.

USE - For treating or preventing a middle ear infection (claimed) e.g. otitis media in mammals including humans.

ADVANTAGE - The carrier composition comprising nonionic polymer surfactant and medicament can be delivered across an intact tympanic membrane i.e. one

Gregg Polansky 10/712,849

without tears (e.g. from bursting under pressure) or punctures (e.g. from insertion of tubes or injection). The nonionic polymer surfactants when applied to the tympanic membrane facilitates the transport of a medicament across the membrane and into the middle ear and also modifies the porosity and thus permeability of the tympanic membrane by a magnitude sufficient to permit the medicament to pass into the membrane. The carrier composition is effective in treating middle ear infections and its associated pain and inflammation.

L87 ANSWER 10 OF 1456 WPIX COPYRIGHT 2007 THE THOMSON CORP on STN
 ACCESSION NUMBER: 2007-492968 [48] WPIX
 DOC. NO. CPI: C2007-181704 [48]
 DOC. NO. NON-CPI: N2007-374956 [48]
 TITLE: Device for delivery of therapeutic agents e.g. neurotrophic agent and antibiotic, comprises body having proximal and distal ends with cavity, access port located at proximal end and removable insert
 DERWENT CLASS: A96; B07; D22; P32
 INVENTOR: WEN X
 PATENT ASSIGNEE: (UYCL-N) UNIV CLEMSON
 COUNTRY COUNT: 1

PATENT INFO ABBR.:

PATENT NO	KIND	DATE	WEEK	LA	PG	MAIN IPC
US 20070077270	A1	20070405	(200748)*	EN	17[7]	

APPLICATION DETAILS:

PATENT NO	KIND	APPLICATION	DATE
US 20070077270	A1 Provisional	US 2005-665711P	20050328
US 20070077270	A1	US 2006-390958	20060328

PRIORITY APPLN. INFO: US 2006-390958 20060328
 US 2005-665711P 20050328

AB US 20070077270 A1 UPAB: 20070727
 NOVELTY - A drug delivery device (10) comprises a body (20) having a proximal end and a distal end (22, 24) with a cavity, an access port (30) located at the proximal end and a removable insert. The removable insert has a proximal end and a distal end. The removable insert is configured to be removably inserted into the cavity of body.
 DETAILED DESCRIPTION - An INDEPENDENT CLAIM is included for a method of targeted delivery of therapeutic agent to inner ear or eye.
 USE - For delivering therapeutic agent such as a neurotrophic agent or an antibiotic (claimed) for treating ocular diseases e.g. retinal degeneration, retinal detachment, proliferative retinopathy and proliferative diabetic retinopathy and inner ear diseases e.g. deafness, sensorineural hearing loss, autoimmune inner ear disease, Meniere's disease, tinnitus, otitis, otalgia, and other otic diseases.
 ADVANTAGE - The device efficiently delivers the therapeutic agent into inner ear or eye.
 DESCRIPTION OF DRAWINGS - The figure shows the structure of body of the delivery device.
 Delivery device (10)
 Body (20)
 Distal and proximal end (22,24) Access port (30)

L87 ANSWER 11 OF 1456 WPIX COPYRIGHT 2007 THE THOMSON CORP on STN
 ACCESSION NUMBER: 2007-485683 [48] WPIX
 DOC. NO. CPI: C2007-178604 [48]
 DOC. NO. NON-CPI: N2007-368948 [48]
 TITLE: Film for tissue culture reproduction occlusion of eardrum perforation used in surgical treatment of e.g. chronic otitis, has activator mixed with atherocollagen film for eardrum and impregnated with concentrated blood platelets plasma
 DERWENT CLASS: B04; P32; P34
 INVENTOR: YOSHIDA K
 PATENT ASSIGNEE: (YOSH-I) YOSHIDA K
 COUNTRY COUNT: 1

PATENT INFO ABBR.:

PATENT NO	KIND	DATE	WEEK	LA	PG	MAIN IPC
JP 2007075136	A	20070329	(200748)*	JA	4[0]	

APPLICATION DETAILS:

PATENT NO	KIND	APPLICATION	DATE
JP 2007075136	A	JP 2005-262707	20050909

PRIORITY APPLN. INFO: JP 2005-262707 20050909

AB JP 2007075136 A UPAB: 20070727

NOVELTY - The film contains an activator that consists of self-thrombin and calcium chloride, and that is mixed with atherocollagen film with 1 to 2 millimeter thickness for eardrum. The activator is impregnated with 0.1 to 0.3 milliliter of concentrated blood platelets plasma (PRP) extracted twice from the patient's autologous blood using centrifuge method.

USE - For tissue culture reproduction occlusion of eardrum perforation used in surgical treatment of e.g. chronic otitis, tympanotomy, eardrum tube indwelling.

ADVANTAGE - Provides a simple and cost-effective technique for the occlusion of eardrum perforation. Provides a very effective therapeutic procedure for patients, especially children, who hesitate in surgery.

L87 ANSWER 12 OF 1456 WPIX COPYRIGHT 2007 THE THOMSON CORP on STN

ACCESSION NUMBER: 2007-476533 [46] WPIX
 DOC. NO. CPI: C2007-173933 [46]
 DOC. NO. NON-CPI: N2007-362212 [46]
 TITLE: Assessing a patient's risk of developing otitis media (OM) or its progression or assisting in the diagnosis of OM by determining the amount or function of FBXO11 polypeptide or nucleic acid and the patient's genotype for FBXO11
 DERWENT CLASS: B04; D16; S03
 INVENTOR: BROWN S D M; HARDISTY-HUGHES R E
 PATENT ASSIGNEE: (MEDI-N) MEDICAL RES COUNCIL
 COUNTRY COUNT: 115

PATENT INFO ABBR.:

PATENT NO	KIND	DATE	WEEK	LA	PG	MAIN IPC
WO 2007039759	A1	20070412	(200746)*	EN	71[6]	

APPLICATION DETAILS:

PATENT NO	KIND	APPLICATION	DATE
WO 2007039759	A1	WO 2006-GB3731	20061006

PRIORITY APPLN. INFO: GB 2005-20311 20051006

AB WO 2007039759 A1 UPAB: 20070719

NOVELTY - Assessing a patient's risk of developing otitis media (OM) or progression of OM or assisting in the diagnosis of OM, comprises (i) obtaining a sample containing nucleic acid and/or protein from the patient; and (ii) determining one or more of: (a) the amount and/or function of FBXO11 polypeptide; (b) the amount of nucleic acid encoding FBXO11; and (c) the patient's genotype for FBXO11.

DETAILED DESCRIPTION - INDEPENDENT CLAIMS are: (1) use of an agent which is capable of being used in determining one or more of the amount or function of FBXO11 polypeptide or nucleic acid encoding FBXO11, and determining a patient's genotype of FBXO11, in manufacturing a reagent for assessing a patient's risk of developing otitis media (OM); or progression of OM, or for assisting in the diagnosis of OM;

(2) an expression vector comprising a polynucleotide which encodes FBXO11 polypeptide;

(3) a host cell comprising the expression vector; (4) a method of making a FBXO11 polypeptide, or a variant, fragment, derivative or fusion or fusion of a the variant or fragment or derivative;

(5) a gene therapy vector comprising a polynucleotide which encodes FBXO11 polypeptide;

(6) a pharmaceutical composition comprising a polynucleotide encoding FBXO11 or FBXO11 polypeptide or a gene therapy vector and a pharmaceutically acceptable carrier; (7) a polynucleotide encoding FBXO11 or FBXO11 polypeptide, gene therapy vector or pharmaceutical composition for use in medicine; (8) a method of treating a patient with or at risk of developing OM by administering to the patient an appropriate quantity of a polynucleotide encoding FBXO11 or FBXO11 polypeptide, gene therapy vector or pharmaceutical composition;

(9) a method for generating a non-human animal which develops OM; (10) an isolated or recombinant nucleic acid encoding FBXO11 in which the residue corresponding to Q491 is mutated, for example to L; or in which the residue corresponding to S244 is mutated, e.g., to L; (11) a method for identifying a putative substrate polypeptide for FBXO11 polypeptide;

(12) a method for identifying a polypeptide involved in OM; (13) a method of generating a non-human animal which develops OM; (14) a kit of parts useful for assessing a patient's risk of developing otitis media (OM); or progression of OM; or for assisting in the diagnosis of OM, comprising one or more agents useful in determining one or more of: (a) the amount or function of FBXO11 polypeptide; (b) the amount of nucleic acid encoding FBXO11; (c) the patient's genotype for FBXO11; and, optionally, (d) a positive or negative control; and (15) a method for identifying a compound expected to be useful in treating or preventing OM.

ACTIVITY - Auditory. No biological data given.

MECHANISM OF ACTION - Vaccine.

USE - The agent which is capable of being used in determining one or more of the amount or function of FBXO11 polypeptide or nucleic acid encoding FBXO11, and determining a patient's genotype of FBXO11, in manufacturing a reagent for assessing a patient's risk of developing otitis media (OM); or progression of OM, or for assisting in the diagnosis of OM. The polynucleotide encoding FBXO11 or FBXO11 polypeptide, gene therapy vector or pharmaceutical composition is useful in manufacturing a medicament for treating or preventing

Gregg Polansky 10/712,849

OM. The modulator, e.g., inhibitor of an E3 ubiquitin ligase is useful in manufacturing a medicament for treating or preventing acute or chronic OM.

L87 ANSWER 13 OF 1456 WPIX COPYRIGHT 2007 THE THOMSON CORP on STN
 ACCESSION NUMBER: 2007-473752 [46] WPIX
 DOC. NO. NON-CPI: N2007-359731 [46]
 TITLE: Method for preventing atrophic retraction and adhesion of
 tympanic membrane taking place in exudative
 otitis cases
 DERWENT CLASS: P32
 INVENTOR: ANIKIN I A; ANIKIN M I; CHERNUSHEVICH I I; DIAB KH;
 SITNIKOV V P
 PATENT ASSIGNEE: (SPET-R) ST PETERSBURG EAR THROAT SPEECH RES INST
 COUNTRY COUNT: 1

PATENT INFO ABBR.:

PATENT NO	KIND	DATE	WEEK	LA	PG	MAIN IPC
RU 2302223	C1	20070710	(200746)*	RU	[0]	

APPLICATION DETAILS:

PATENT NO	KIND	APPLICATION	DATE
RU 2302223	C1	RU 2005-134517	20051101

PRIORITY APPLN. INFO: RU 2005-134517 20051101

AB RU 2302223 C1 UPAB: 20070719
 NOVELTY - Method involves inspecting tympanic cavity with cicatrices and polyps being removed, isolating tympanic membrane from middle ear structures, and strengthening atrophied membrane segment by means of a support member. Soft tissues are separated in mastoid process and external acoustic meatus posterior wall skin area, meatotympanic graft is detached, the tympanic membrane is isolated and its atrophied membrane is strengthened in one stage with one element like 40-50 mcm thick allotendon plate. One edge of the plate is set with a support on posterior wall bone of external acoustic meatus and fixed with external acoustic meatus skin when returning the meatotympanic graft on a its place, retaining the other edge in partially mobile state adjoining to tympanic membrane internal surface and overlapping the atrophied site by 0.5-1 mm.
 USE - Medicine.
 ADVANTAGE - Avoided repeated surgical intervention.2 cl, 2 dwg

L87 ANSWER 14 OF 1456 WPIX COPYRIGHT 2007 THE THOMSON CORP on STN
 ACCESSION NUMBER: 2007-445302 [43] WPIX
 CROSS REFERENCE: 2004-439866
 DOC. NO. CPI: C2007-161837 [43]
 TITLE: Medical kit for use in treating middle and inner ear
 conditions, e.g. otitis media, comprises
 flowable aqueous formulation containing viscogenic agent
 and pharmacologic agent(s), and instructions for using
 formulation
 DERWENT CLASS: A96; B02; B03; B07
 INVENTOR: CHEUNG B W Y; SAWCHUK R J
 PATENT ASSIGNEE: (MINU-C) UNIV MINNESOTA
 COUNTRY COUNT: 1

PATENT INFO ABBR.:

PATENT NO	KIND	DATE	WEEK	LA	PG	MAIN IPC
US 20070098679	A1	20070503	(200743)*	EN	10	[2]

APPLICATION DETAILS:

PATENT NO	KIND	APPLICATION	DATE
US 20070098679	A1 Cont of	US 2002-306517	20021127
US 20070098679	A1	US 2006-614266	20061221

PRIORITY APPLN. INFO: US 2006-614266 20061221
 US 2002-306517 20021127

AB US 20070098679 A1 UPAB: 20070706

NOVELTY - A medical kit comprises an aqueous formulation, and instructions indicating that the formulation is to be applied to a tympanic membrane. The formulation contains viscogenic agent and pharmacologic agent(s), is flowable and has a viscosity of less than 100000 cPs. After application to the tympanic membrane, the formulation forms a gel having a yield stress sufficient to maintain the formulation against the tympanic membrane. The formulation allows for transfer of pharmacologic agent across the tympanic membrane and into the middle ear space.

ACTIVITY - Auditory. No biological data given.

MECHANISM OF ACTION - None given.

USE - For applying aqueous formulation to the ear for treating middle and inner ear conditions, e.g. otitis media.

ADVANTAGE - Delivery of aqueous composition to the tympanic membrane provides more effective ways to treat middle and inner ear disorders, e.g. otitis media.

L87 ANSWER 15 OF 1456 WPIX COPYRIGHT 2007 THE THOMSON CORP on STN

ACCESSION NUMBER: 2007-434428 [41] WPIX

CROSS REFERENCE: 2007-533740

DOC. NO. CPI: C2007-157584 [41]

TITLE: New piperidine derivatives are chemokine receptor 1 inhibitors useful for the treatment of e.g. inflammatory condition, immunoregulatory disorder, rheumatoid arthritis and multiple sclerosis

DERWENT CLASS: B02; B03; D22

INVENTOR: CHEN W; GREENMAN K L; LI L; PENNELL A; PENNELL A M K; SULLIVAN E J; ZHANG P; ARALDI G; ROHSHEIM M

PATENT ASSIGNEE: (CHEM-N) CHEMOCENTRYX INC

COUNTRY COUNT: 115

PATENT INFO ABBR.:

PATENT NO	KIND	DATE	WEEK	LA	PG	MAIN IPC
WO 2007044804	A2	20070419	(200741)*	EN	86	[7]
US 20070088036	A1	20070419	(200741)	EN		
US 20070093467	A1	20070426	(200741)	EN		
WO 2007073432	A2	20070628	(200746)	EN		

APPLICATION DETAILS:

PATENT NO	KIND	APPLICATION	DATE
-----------	------	-------------	------

Gregg Polansky 10/712,849

WO 2007044804 A2	WO 2006-US39713 20061011
US 20070088036 A1 Provisional	US 2005-725980P 20051011
US 20070093467 A1 Provisional	US 2005-725980P 20051011
US 20070088036 A1	US 2006-546938 20061011
US 20070093467 A1	US 2006-580202 20061011
WO 2007073432 A2	WO 2006-US39980 20061011

PRIORITY APPLN. INFO: US 2005-725980P 20051011
 US 2006-546938 20061011
 US 2006-580202 20061011

AB WO 2007044804 A2 UPAB: 20070629

NOVELTY - Piperidine derivatives (I) and their salts and N-oxides are new.

DETAILED DESCRIPTION - Piperidine derivatives of formula (I) and their salts and N-oxides are new.

R1=e.g. 1-8C alkyl or 1-8C haloalkyl; m'=0 - 4;

R2a-R2e=e.g. H, halo, -CN or -NO₂; B'=e.g. (hetero)aryl (optionally substituted with 1-5 R₃); R3=e.g. halo, -CN or -NO₂;

L1=e.g. 1-4C alkylene or heteroalkylene; and A=e.g. H or (hetero)aryl.

The full definitions are given in the DEFINITIONS (Full Definitions) field.

INDEPENDENT CLAIMS are included for the following: (1) a pharmaceutical composition (C1) comprising (I) and excipient or carrier; and

(2) treatment (m1) of chemokine receptor 1 (CCR1)-mediated diseases or conditions involving administering the piperidine derivative (I). ACTIVITY - Antiinflammatory; Antirheumatic; Antiarthritic; Dermatological;

Neuroprotective; Nootropic; Immunosuppressive; Vasotropic; Gastrointestinal-Gen.; Antiallergic; Antiasthmatic; Antiparkinsonian; Antipsoriatic;

Osteopathic; Cerebroprotective; Antiulcer; Antipruritic; Respiratory-Gen.;

Antidiabetic; Nephrotropic; Hepatotropic; Cardiovascular-Gen.;

Antiartherosclerotic; Antiangiogenic; Virucide; Antibacterial;

Ophthalmological; Auditory; Vulnerary; Anti-HIV; Cytostatic.

MECHANISM OF ACTION - Chemokine receptor 1 (CCR1) inhibitor. Inhibition of CCR1 ligand binding by 1-(2-(4-chloro-5-methyl-3-trifluoromethyl-pyrazol-1-yl)-acetyl)-4-(4-chloro-phenyl)-piperidine-4-carbonitrile (IA) was tested as follows: CCR1 expressing cells were centrifuged and resuspended in assay buffer containing 4-(2-hydroxyethyl)-1-piperazine ethane sulfonic acid (HEPES) (20 mM) pH 7.1, NaCl (140 mM), CaCl₂ (1 mM), MgCl₂ (5 mM), and with bovine serum albumin (0.2%) to a concentration of 5x10⁶ cells/ml for THP (tetrahydropyran)-1 cells and 5x10⁵ for monocytes. The cells (0.1 ml) were added to the assay plates containing (IA). Then 125I labeled macrophage inflammatory protein (MIP)-1 α (0.1 ml) or 125I labeled CCL15 (chemokine leukotactin)/leukotactin (0.1 ml) diluted in assay buffer was added and the plates were sealed and incubated for 3 hours at 4degreesC. The reactions were aspirated in polyethyleneimine (PEI) solution (0.3%). The IC₅₀ value for (IA) was calculated, which was found to be less than 1000 nM.

USE - For the treatment of CCR1-mediated diseases or conditions e.g. inflammatory condition, immunoregulatory disorder, rheumatoid arthritis, multiple sclerosis, transplant rejection, restenosis, dermatitis, eczema, urticaria, vasculitis, inflammatory bowel disease, food allergy, asthma, Alzheimer's disease, Parkinson's disease, psoriasis, lupus erythematosus, osteoarthritis, stroke and encephalomyelitis (all claimed); for the treatment of diseases associated with CCR1, CCR2 and CCR3 signaling activity; for the treatment of diseases or conditions including chronic diseases of human or other species can be treated with modulators of CCR1, CCR2 or CCR3 function (e.g. allergic diseases such as systemic anaphylaxis or hypersensitivity responses, drug allergies, insect sting allergies; Crohn's disease, ulcerative colitis; vaginitis; allergic contact dermatitis, pruritus; spondyloarthropathies; respiratory allergic diseases such as hypersensitivity lung diseases; Still's disease, type I diabetes, type II diabetes, type I diabetes (recent onset), optic neuritis, graft rejection including allograft rejection and acute and chronic graft-versus-host disease; hepatic fibrosis

(including that caused by alcoholic or viral hepatitis), primary and secondary cirrhosis); other diseases in which undesired inflammatory responses or immune disorders are to be inhibited, such as cardiovascular disease including atherosclerosis, vascular inflammation resulting from tissue transplant or during restenosis (including restenosis following angioplasty and/or stent insertion), other acute and chronic inflammatory conditions such as myositis, neurodegenerative diseases (e.g. Alzheimer's disease), encephalitis, meningitis, hepatitis, nephritis, sepsis, allergic conjunctivitis, otitis, sinusitis, synovial inflammation caused by arthroscopy, hyperuremia, trauma, ischemia reperfusion injury, nasal polyosis, preeclampsia, oral lichen planus, Guillain-Barre syndrome, granulomatous diseases, conditions associated with leptin production, Behcet's syndrome and gout and in wound healing applications; immune mediated food allergies such as Celiac disease); for the treatment of diseases or conditions treated with modulators of CCR1 function (e.g. cancers (both primary and metastatic); infectious diseases (viral infections, e.g. HIV infection, and bacterial infections) and immunosuppressive diseases such as organ transplant conditions and skin transplant conditions); and in assays for the identification of competitive CCR1 antagonists.

ADVANTAGE - The compounds are potent antagonists of CCR1 receptors and have in vivo anti-inflammatory activity.

L87 ANSWER 16 OF 1456 WPIX COPYRIGHT 2007 THE THOMSON CORP on STN
 ACCESSION NUMBER: 2007-414040 [40] WPIX
 DOC. NO. CPI: C2007-150338 [40]
 TITLE: Medicine for treating otitis media
 DERWENT CLASS: B04; B07
 INVENTOR: GUAN R; LIU T
 PATENT ASSIGNEE: (LIUT-I) LIU T
 COUNTRY COUNT: 1

PATENT INFO ABBR.:

PATENT NO	KIND	DATE	WEEK	LA	PG	MAIN IPC
CN 1903218	A	20070131	(200740)*	ZH	[0]	

APPLICATION DETAILS:

PATENT NO	KIND	APPLICATION	DATE
CN 1903218 A		CN 2006-10041264	20060730

PRIORITY APPLN. INFO: CN 2006-10041264 20060730

AB CN 1903218 A UPAB: 20070625

NOVELTY - A Chinese medicine in the form of powder for treating tympanitis is proportionally prepared from realgar, sulfur, roasted alum, sliced plum and musk through proportional mixing, breaking, grinding, and sieving.

L87 ANSWER 17 OF 1456 WPIX COPYRIGHT 2007 THE THOMSON CORP on STN
 ACCESSION NUMBER: 2007-413117 [39] WPIX
 DOC. NO. CPI: C2007-149643 [39]
 TITLE: New substituted benzofused compounds are vanilloid receptor antagonists useful to prevent/ameliorate/treat e.g. asthma, ulcerative colitis, urinary incontinence and chronic pain
 DERWENT CLASS: B02
 INVENTOR: GHARAT L A; JOSHI N K; JOSHI U M

PATENT ASSIGNEE: (GLEN-N) GLENMARK PHARM SA
 COUNTRY COUNT: 115

PATENT INFO ABBR.:

PATENT NO	KIND	DATE	WEEK	LA	PG	MAIN IPC
WO 2007042906	A1	20070419	(200739)*	EN	121	[0]

APPLICATION DETAILS:

PATENT NO	KIND	APPLICATION	DATE
WO 2007042906	A1	WO 2006-IB2814	20061009

PRIORITY APPLN. INFO: US 2006-807205P 20060713
 IN 2005-MU1269 20051007
 US 2005-730660P 20051026
 IN 2006-MU996 20060626

AB WO 2007042906 A1 UPAB: 20070620

NOVELTY - Substituted benzofused compounds (I) and their analogs, salts, solvates, hydrates, N-oxides, tautomers, regioisomers, stereoisomers, prodrugs and polymorphs are new.

DETAILED DESCRIPTION - Substituted benzofused compounds of formula (I) and their analogs, salts, solvates, hydrates, N-oxides, tautomers, regioisomers, stereoisomers, prodrugs and polymorphs are new. X, Y1 = O, S(O)m or NRe; R1R2 = optionally substituted and saturated 3-7 membered cyclic ring (optionally include heteroatoms of O, NR9 or S(O)m); either R3, R4 = alkyl (optionally substituted), H, CN, halo, OR9 or NR9R10; or R3+R4 = oxo; either R5-R7 = alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, cycloalkenyl, cycloalkenylalkyl, arylalkyl, (hetero)aryl, heteroarylalkyl, heterocyclic, heterocyclalkyl (all optionally substituted), H, NO2, CN, halo, OR9, NR9R10, C(=L)-R9, C(O)O-R9, C(O)NR9R10, S(O)m-R9 or S(O)m-NR9R10; either R8 = alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, cycloalkenyl, cycloalkenylalkyl, arylalkyl, (hetero)aryl, heteroarylalkyl, heterocyclic, heterocyclalkyl (all optionally substituted), NR9R10, C(=L)-R9, C(O)O-R9, C(O)NR9R10, S(O)m-R9 or S(O)m-NR9R10 or H; or R7+R8 = optionally substituted and saturated 3-7 membered cyclic ring (optionally include 0-2 heteroatoms of O, NRe or S); either R9, R10 = alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, cycloalkenyl, cycloalkenylalkyl, arylalkyl, (hetero)aryl, heteroarylalkyl, heterocyclic, heterocyclalkyl (all optionally substituted), H, ORa, SRa, NRaRb, C(=L)-Ra, C(O)O-Ra, C(O)NRaRb, S(O)m-Ra or S(O)m-NRaRb; or NR9+R10 = 3-7 membered cyclic ring (optionally include at least two heteroatoms of O, NRe or S); either Ra, Rb = alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, cycloalkenyl, cycloalkenylalkyl, arylalkyl, (hetero)aryl, heteroarylalkyl, heterocyclic, heterocyclalkyl (all optionally substituted), H, ORc, SRC, C(=L)-Rc, C(O)O-Rc, C(O)NRcRd, S(O)m-Rc, S(O)m-NRcRd, NRcRd or protecting group; or NRa+Rb = optionally substituted and saturated 3-7 membered cyclic ring (optionally include at least two heteroatoms of O, NRe or S); either Rc, Rd = alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, cycloalkenyl, cycloalkenylalkyl, arylalkyl, (hetero)aryl, heteroarylalkyl, heterocyclic, heterocyclalkyl (all optionally substituted), H or protecting group; or NRc+Rd = 3-7 membered cyclic ring, optionally include at least two heteroatoms from O, NRe or S; Re = alkyl (optionally substituted) or H; L = O, S or NRe; m = 0-2; and n = 0-4.

An INDEPENDENT CLAIM is included for the preparation of (I). ACTIVITY - Uropathic; Antiinflammatory; Antiasthmatic; Antiulcer; Gastrointestinal-Gen; Analgesic; antiinflammatory; gastrointestinal-gen.; Immunosuppressive; Antiallergic; Respiratory-Gen; Dermatological; Antipruritic; Anticonvulsant; Antiemetic; Muscular-Gen ; Antidepressant; Nootropic; Cerebroprotective ; Neuroprotective; Antiarthritic; Osteopathic; Antidiabetic; Anorectic; keratolytic; dermatological; Endocrine-Gen; Auditory; Tranquilizer; Cytostatic; Ophthalmological; Vasotropic; Gynecological.

MECHANISM OF ACTION - Vanilloid receptor 1 antagonist. The ability of (I) to antagonize vanilloid receptor 1 was tested using a 45 calcium uptake assay. The result showed that the percentage inhibition of vanilloid receptor 1 by (plus minus)1 (3,4-dihydro-1'-(methyl)spiro-(2H-1-benzopyran-2,4'-piperidine)-4-yl)-3-(isoquinoline-5-yl)urea was 142.29% at 1 μ M.

USE - (I) are useful to prevent/ameliorate/treat a vanilloid receptor mediated disease, disorder or syndrome, where the disease, disorder or syndrome is urinary incontinence, inflammation, asthma, ulcerative colitis, pain such as acute pain, chronic pain, neuropathic pain, post-operative pain (all preferred), nociceptive pain, dental pain, cancer pain, cardiac pain arising from an ischemic myocardium, pain due to migraine, arthralgia, neuropathies, neuralgia and trigeminal neuralgia nerve injury, diabetic neuropathy, neurodegeneration, retinopathy, neurotic skin disorder, stroke, urinary bladder hypersensitiveness, vulvodynia, gastrointestinal disorders such as irritable bowel syndrome, gastro-esophageal reflux disease, enteritis, ileitis, stomach-duodenal ulcer, inflammatory bowel disease, Crohn's disease, celiac disease, inflammatory disease (such as pancreatitis), respiratory disorder such as allergic and non-allergic rhinitis, chronic obstructive pulmonary disease, irritation of skin, eye or mucous membrane, dermatitis, pruritic conditions such as uremic pruritus, ferveescence, muscle spasms, emesis, dyskinesias, depression, Huntington's disease, memory deficits, restricted brain function, amyotrophic lateral sclerosis, dementia, arthritis, osteoarthritis, diabetes, obesity, urticaria, actinic keratosis, keratocanthoma, alopecia, Meniere's disease, tinnitus, hyperacusis , anxiety disorders and benign prostate hyperplasia (claimed).

ADVANTAGE - (I) are effective and safe to treat diseases, conditions and/or disorders modulated by vanilloid receptors.

L87 ANSWER 18 OF 1456 WPIX COPYRIGHT 2007 THE THOMSON CORP on STN
 ACCESSION NUMBER: 2007-413046 [39] WPIX
 DOC. NO. CPI: C2007-149572 [39]
 TITLE: New tetrahydro-pyrrolo (1,2-b)isothiazole 1,1-dioxides
 useful for treating disorders associated with conditions
 of immune system, inflammation and transplantation e.g.
 asthma, Hashimoto's disease, multiple sclerosis,
 rheumatoid arthritis
 DERWENT CLASS: A96; B02
 INVENTOR: BAUMANN K
 PATENT ASSIGNEE: (NOVS-C) NOVARTIS AG; (NOVS-C) NOVARTIS PHARMA GMBH
 COUNTRY COUNT: 115

PATENT INFO. ABBR.:

PATENT NO	KIND	DATE	WEEK	LA	PG	MAIN IPC
WO 2007039616	A1	20070412	(200739)*	EN	35	[0]

APPLICATION DETAILS:

PATENT NO	KIND	APPLICATION	DATE

PRIORITY APPLN. INFO: GB 2005-20378

20051006

AB WO 2007039616 A1 UPAB: 20070620

NOVELTY - Tetrahydro-pyrrolo (1,2-b)isothiazole 1,1-dioxides are new.

DETAILED DESCRIPTION - Tetrahydro-pyrrolo (1,2-b)isothiazole 1,1-dioxides of formula (I) are new. a=single or double bond;

R1=alkyl, alkenyl, alkynyl, cycloalkyl, alkoxy, aryl or heterocyclyl (all optionally substituted), H, OH, SH, SR5, cyano, halo or amino;

R2=H or optionally substituted cycloalkyl, aryl, or heterocyclyl; R3=H, COOR6, aminocarbonyl, or optionally substituted alkyl, alkenyl, alkynyl, aralkyl, alkoxy, cycloalkyloxy, aryloxy, or heterocycloxy;

R4=H, halo, OH, SH, optionally substituted alkyl, alkenyl, alkynyl, alkoxy or alkylthio, or a silyl group such as trialkylsilyl or trialkylsilyloxy, e.g. tri(1-6C)alkylsilyl(oxy), N3, amino, or heterocyclyl comprising at least one nitrogen atom and is bound via that nitrogen atom to (I) or R4 is attached to the ring system by a double bond and is oxo; and

R5 and R6=alkyl, alkenyl, alkynyl, cycloalkyl, aryl or heterocyclyl.

An INDEPENDENT CLAIM is included for a pharmaceutical combination comprising tetrahydro-pyrrolo (1,2-b)isothiazole 1,1-dioxides (I) in combination with at least one second drug substance. ACTIVITY - Antiinflammatory;

Ophthalmological; Cardiant; Antiasthmatic; Respiratory-Gen.; Dermatological; Antiallergic and/or immunosuppressive; Neuroprotective; Osteopathic; Antithyroid; Thyromimetic; Antiarthritic; Antirheumatic; Antigout; Antipsoriatic; Gastrointestinal-Gen.; Antiulcer; Antibacterial; Antianemic; Antiallergic; Antidiabetic; Nephrotropic; Virucide; Vasotropic; CNS-Gen.; Antiseborrheic; Anti-HIV; Hepatotropic; Antiinfertility; Endocrine-Gen.; Gynecological; Immunomodulator; Cerebroprotective; Muscular-Gen.; Antimicrobial; Antimalarial; Fungicide.

MECHANISM OF ACTION - Lymphocyte function associated antigen 1 (LFA-1)/intercellular adhesion molecule (ICAM) inhibitor. Test details described. No specific results given.

USE - For the preparation of medicament for treating disorders mediated by interactions of LFA-1 (lymphocyte function associated antigen 1) with its ligands involved in cell adhesion, migration or activation (claimed); for treating disorders associated with inflammatory conditions e.g. (chronic) inflammatory disorders, e.g. bronchitis, cervicitis, conjunctivitis, esophagitis, myocarditis, pulmonary inflammation (alveolitis), airways, e.g. asthma, such as bronchial asthma, acute respiratory distress syndrome (ARDS), inflammatory skin disorders such as contact hypersensitivity, (allergic) contact dermatitis, atopic dermatitis, fibrotic disease (e.g. pulmonary fibrosis), encephalitis, inflammatory osteolysis, disorders associated with conditions of the immune system, such as autoimmune disorders e.g. including Graves' disease, Hashimoto's disease (chronic thyroiditis), multiple sclerosis, rheumatoid arthritis, arthritis, gout, osteoarthritis, scleroderma, lupus syndromes, systemic lupus erythematosus, psoriasis, inflammatory bowel disease, including Crohn's disease, colitis, e.g. ulcerative colitis, sepsis, septic shock, autoimmune hemolytic anemia (AHA), autoantibody triggered urticaria, pemphigus, nephritis, glomerulonephritis, Goodpasture syndrome, ankylosing spondylitis, Reiter's syndrome, polymyositis, dermatomyositis, cytokine-mediated toxicity, interleukin-2 toxicity, alopecia, e.g. alopecia areata, hair growth, uveitis, lichen planus, bullous pemphigoid, myasthenia gravis, type I diabetes mellitus, immune-mediated infertility such as premature ovarian failure, polyglandular failure, hypothyroidism, pemphigus vulgaris, pemphigus l-oliaceus, paraneoplastic pemphigus, autoimmune hepatitis including that associated with hepatitis B virus (HBV) and hepatitis C virus (HCV), Addison's disease, autoimmune skin diseases, dermatitis herpetiformis, epidermolysis bullosa, linear IgA bullous dermatosis, epidermolysis bullosa acquisita chronic bullous disease of childhood, pernicious anemia, hemolytic anemia, vitiligo, type I, type II and type III autoimmune polyglandular

syndromes, autoimmune hypoparathyroidism, autoimmune hypophysitis, autoimmune oophoritis, autoimmune orchitis, pemphigoid gestationis, cicatricial pemphigoid, mixed essential cryoglobulinemia, immune thrombocytopenic purpura, Good pasture's syndrome, autoimmune neutropenia, Eaton-Lambert myasthenic syndrome, stiff-man syndrome, encephalomyelitis, acute disseminated encephalomyelitis, Guillain-Barre syndrome, cerebellar degeneration, retinopathy, primary biliary sclerosis, sclerosing cholangitis autoimmune hepatitis, gluten-sensitive enteropathy, reactive arthritides, polymyositis/dermatomyositis, mixed connective tissue disease, Behcet's syndrome, polyarteritis nodosa allergic anguitis and granulomatosis (Churg-Strauss disease), polyangiitis overlap syndrome (hypersensitivity) vasculitis, Wegener's granulomatosis, temporal arteritis Kawasaki's disease, sarcoidosis, cryopathies, Celiac disease, disorders associated with skin and connective tissue conditions e.g. eczema, atopic dermatitis, (allergic) contact dermatitis, psoriasis, acne, dermatomyositis, Sjorgen's syndrome, Churg-Struass syndrome, sunburn, skin cancer urticaria, toxic epidermal necrolysis, age related skin conditions, cellulite, disorders associated with allergic conditions, e.g. including delayed-type hypersensitivity, allergic conjunctivitis, drug allergies, rhinitis, allergic rhinitis, vasculitis, contact dermatitis, disorders associated with infectious disorders, e.g. with chronic infectious conditions, e.g. including bacterial disorders, otitis media, lyme disease, thyroiditis, viral disorders parasitic disorders, fungal disorders, malaria, e.g. malaria, anemia, sepsis, severe sepsis, septic shock, e.g. endotoxin-induced septic shock, exotoxin-induced toxic shock, infective (true septic) shock, septic shock caused by Gram-negative bacteria, pelvic inflammatory disease, AIDS, enteritis, pneumonia, meningitis, encephalitis, disorders associated with transplantation, e.g. including transplant rejection crisis and other disorders following transplantation, such as organ or tissue (xeno)transplant rejection, e.g. for the treatment of recipients of e.g. heart, lung, combined heart-lung, liver, kidney, pancreatic, skin, corneal transplants, graft versus host disease, such as following bone marrow transplantation, ischemic reperfusion injury.

ADVANTAGE - The compounds exhibits valuable pharmacological properties, e.g by mediating such as inhibiting the activity of LFA-1 (lymphocyte function associated antigen 1) interactions with its ligands, e.g. inhibiting the activity of LFA-1/ICAM-1 (intercellular adhesion molecule-1), LFA-1/ICAM-2, LFA-1/ICAM-3 and/or LFA-1/JAM-1 (junctional adhesion molecule 1) interactions e.g. LFA-1/ICAM-1 interaction, and thus mediating, e.g. inhibiting inflammation.

L87 ANSWER 19 OF 1456 WPIX COPYRIGHT 2007 THE THOMSON CORP on STN

ACCESSION NUMBER: 2007-412855 [39] WPIX

DOC. NO. CPI: C2007-149491 [39]

TITLE: Identifying a subject at risk of, or having, an indication associated with altered innate immunity by detecting the presence or absence of at least one nucleic acid variant in at least one Toll-like receptor (TLR) gene or its part

DERWENT CLASS: B04; D16

INVENTOR: NUYTINCK L

PATENT ASSIGNEE: (INNO-N) INNOGENETICS NV

COUNTRY COUNT: 115

PATENT INFO ABBR.:

PATENT NO	KIND	DATE	WEEK	LA	PG	MAIN IPC
WO 2007025989	A2	20070308	(200739)*	EN	186[4]	

APPLICATION DETAILS:

PATENT NO	KIND	APPLICATION	DATE
WO 2007025989 A2		WO 2006-EP65821	20060830

PRIORITY APPLN. INFO: US 2005-717527P 20050915
EP 2005-108074 20050902

AB WO 2007025989 A2 UPAB: 20070620

NOVELTY - Identifying a subject at risk of, or having, an indication associated with altered innate immunity, comprises detecting the presence or absence of at least one nucleic acid variant in at least one Toll-like receptor (TLR) gene, or its part, where the presence of at least one nucleic acid variant identifies whether a subject is at risk or has an indication associated with an altered innate immunity.

DETAILED DESCRIPTION - INDEPENDENT CLAIMS are: (1) a diagnostic kit for identifying a subject at risk of, or having, an indication associated with altered innate immunity, comprising: (a) a means for detecting the presence or absence of one or more nucleic acid variants in at least one TLR gene; and (b) a means for determining, from the nucleic acid variant detected with the means of step (a), whether the subject is at risk of, or has, an indication associated with altered innate immunity;

(2) a method for selecting an appropriate treatment or therapeutic agent for a subject at risk of, or having, an indication associated with altered innate immunity;

(3) an isolated oligonucleotide consisting of 10 to 30 nucleotides for detecting the presence of one or more nucleic acid variants in at least on TLR gene; and

(4) a pair of primers suitable for amplifying a target TLR polynucleic acid.

USE - The method is useful in identifying a subject at risk of, or having, an indication associated with altered innate immunity or in selecting an appropriate treatment or therapeutic agent for a subject at risk of, or having, an indication associated with altered innate immunity (claimed).

L87 ANSWER 20 OF 1456 WPIX COPYRIGHT 2007 THE THOMSON CORP on STN

ACCESSION NUMBER: 2007-405068 [39] WPIX

DOC. NO. CPI: C2007-146849 [39]

TITLE: Decoction medicine for treating acute otitis media and its preparation

DERWENT CLASS: B04

INVENTOR: JIANG G; MING W

PATENT ASSIGNEE: (JIAN-I) JIANG G

COUNTRY COUNT: 1

PATENT INFO ABBR.:

PATENT NO	KIND	DATE	WEEK	LA	PG	MAIN IPC
CN 1895467	A	20070117	(200739)*	ZH	[0]	

APPLICATION DETAILS:

PATENT NO	KIND	APPLICATION	DATE
CN 1895467 A		CN 2006-10092020	20060610

PRIORITY APPLN. INFO: CN 2006-10092020 20060610

AB CN 1895467 A UPAB: 20070620

NOVELTY - A Chinese medicine in the form of decoction for treating acute tympanitis is prepared from 10 Chinese-medicinal materials including honeysuckle flower, red tuckahoe, coptis root, rhubarb, etc. Its preparing process is also disclosed.

L87 ANSWER 21 OF 1456 WPIX COPYRIGHT 2007 THE THOMSON CORP on STN
 ACCESSION NUMBER: 2007-403528 [38] WPIX
 DOC. NO. CPI: C2007-145847 [38]
 TITLE: New growth factors, e.g. NsG29 or Ns31, useful for treating central nervous system disorders or for diseases related to testis, including male sterility, impotence, erectile dysfunction, or cancer
 DERWENT CLASS: B04; D16
 INVENTOR: BLOM N; BRUNAK S; GRONBORG M; JOHANSEN T E; KUSK P; PETERSEN T N; WAHLBERG L U
 PATENT ASSIGNEE: (NSGE-N) NSGENE AS
 COUNTRY COUNT: 111

PATENT INFO ABBR.:

PATENT NO	KIND	DATE	WEEK	LA	PG	MAIN IPC
WO 2006072601	A2	20060713	(200738)*	EN	124	[23]

APPLICATION DETAILS:

PATENT NO	KIND	APPLICATION	DATE
WO 2006072601	A2	WO 2006-EP178	20060109

PRIORITY APPLN. INFO: DK 2005-1096 20050801
 DK 2005-35 20050107
 DK 2005-37 20050107
 DK 2005-1097 20050801

AB WO 2006072601 A2 UPAB: 20070615

NOVELTY - An isolated polypeptide for medical use, comprising a sequence selected from:

- (i) SEQ ID NOS: 3-6, 9-12, 15, 16, 18-20, 21, or 23, given in the specification;
- (ii) a variant of the sequence selected from (i), where the variant has at least 70% sequence identity to the stated sequences; or (iii) a biologically active fragment of at least 50 contiguous amino acids of any of (i) or (ii), is new.

DETAILED DESCRIPTION - INDEPENDENT CLAIMS are also included for: (1) an isolated nucleic acid molecule, for medical use, comprising a nucleotide sequence selected from: (i) a nucleotide sequence coding for a polypeptide having the amino acid sequence selected from SEQ ID NOS: 3-6, 9-12, 15, 16, 18-20, 21, or 23;

- (ii) a nucleotide sequence coding for a sequence variant of the amino acid sequence selected from SEQ ID NOS: 3-6, 9-12, 15, 16, 18-20, 21, or 23, where the variant has at least 70% sequence identity to the stated sequences;
- (iii) a nucleotide sequence coding for a biologically active fragment of at least 50 contiguous amino acids of any of (i) or (ii); (iv) a nucleotide sequence selected from SEQ ID NOS: 2, 8, 14, 17, or 22, given in the specification;

- (v) a nucleotide sequence having at least 70% sequence identity to a coding sequence selected from the coding sequence of SEQ ID NO: 2, 8, 14, 17, or 22;

(vi) a nucleic acid sequence of at least 150 contiguous nucleotides of a coding sequence selected from the coding sequence of SEQ ID NOS: 2, 8, 14, 17, or 22;

(vii) the complement of a nucleic acid capable of hybridizing with a nucleic acid molecule having the sequence of the coding sequence of SEQ ID NOS: 2, 8, 14, 17, or 22 under conditions of high stringency; or (viii) the nucleic acid sequence of the complement of any of (i) - (vii);

(2) a vector comprising the nucleic acid molecule; (3) an isolated host cell transfected or transduced with the vector;

(4) a packaging cell line capable of producing an infective virus particle, the virus particle comprising a Retroviridae derived genome comprising a 5' retroviral long terminal repeat (LTR), a tRNA binding site, a packaging signal, a promoter operably linked to a polynucleotide sequence encoding the new polypeptide, an origin of second strand DNA synthesis, and a 3' retroviral LTR; (5) an implantable biocompatible cell device comprising: (i) a semipermeable membrane permitting the diffusion of the new protein and/or a virus vector; and

(ii) a composition of cells or a packaging cell line of (4); (6) a pharmaceutical composition comprising the polypeptide, or the isolated nucleic acid, the expression vector, or a composition of host cells, or a packaging cell line, or an implantable biocompatible cell device, and a pharmaceutical carrier; (7) a method of treating a pathological condition in a subject; (8) a method of expanding a composition of mammalian cells; (9) a method of differentiating a composition of mammalian cells; (10) an antibody capable of binding to the new polypeptide for medical use;

(11) an immunoconjugate comprising the antibody and a conjugate selected from: (i) a cytotoxic agent such as a chemotherapeutic agent, a toxin, or a radioactive isotope;

(ii) a member of a specific binding pair, such as avidin or streptavidin or an antigen; and

(iii) an enzyme capable of producing a detectable product; and (12) a method of preventing apoptosis in a neuronal cell. ACTIVITY - CNS-Gen; Cerebroprotective; Antiparkinsonian; Nootropic; Neuroprotective; Anticonvulsant; Metabolic; Antidiabetic; Nephrotropic; Analgesic; Ophthalmological; Auditory; Cytostatic; Antiinfertility; Vasotropic; Antialcoholic; Antimicrobial; Inotropic; Hypertensive. No biological data given.

MECHANISM OF ACTION - Gene therapy; Cell therapy; Apoptosis inhibitor.

USE - The polypeptide, isolated nucleic acid sequence, expression vector, composition of host cells, packaging cell line, or implantable biocompatible cell device is useful manufacturing a medicament for the treatment of a disease, disorder, or damage associated with the nervous system.

The disease, disorder, or damage involves neuronal apoptosis; injury to the brain, brain stem, the spinal cord, and/or peripheral nerves, including stroke (cerebrovascular ischemia), traumatic brain injury, spinal cord injury, diffuse axonal injury, epilepsy, neuropathy, peripheral neuropathy and associated pain and other symptoms, and where the neurodegenerative disease is thalamic pain; degeneration of neurons and their processes in the brain, brain stem, the spinal cord, and/or the peripheral nerves, including Parkinson's Disease, Alzheimer's Disease, senile dementia, Huntington's Disease, amyotrophic lateral sclerosis (motor neurone disease), neuronal injury associated with multiple sclerosis, and associated symptoms; dysfunction and/or loss of neurons in the brain, brain stem, the spinal cord, and/or peripheral nerves, including metabolic diseases, nutritional deficiency, toxic injury, malignancy, and/or genetic or idiopathic conditions including diabetes, renal dysfunction, alcoholism, chemotherapy, chemical agents, drug abuse, vitamin deficiency, and infection, where the disorder is essential tremor, or where the disease is peripheral neuropathy and associated pain; is associated with the cerebellum, including sensory ataxia, multiple sclerosis, neurodegenerative spinocerebellar disorders, hereditary ataxia, cerebellar

atrophies (such as olivopentocerebellar atrophy (OPCA), Shy-Drager Syndrome (multiple systems atrophy), and alcoholism; degeneration or sclerosis of glia such as oligodendrocytes, astrocytes and Schwann cells in the brain, brain stem, the spinal cord, and the peripheral nerves, including but not limited to multiple sclerosis, optic neuritis, cerebral sclerosis, post-infectious encephalomyelitis, and epilepsy and associated symptoms; the retina, photoreceptors, and associated nerves including retinitis pigmentosa, macular degeneration, glaucoma, diabetic retinopathy, and associated symptoms; the sensory epithelium and associated ganglia of the vestibuloacoustic complex including noise-induced hearing loss, deafness, tinnitus, otitis, labyrinthitis, hereditary and cochleovestibular atrophies, Meniere disease (inner ear disease), and associated symptoms; and the treatment of a disease related to testis, including male sterility (male infertility), impotence, erectile dysfunction, cancer, and germ cell tumors (all claimed).

L98 ANSWER 1 OF 27 CAPLUS COPYRIGHT 2007 ACS on STN DUPLICATE 3
 ACCESSION NUMBER: 2004:430739 CAPLUS Full-text
 DOCUMENT NUMBER: 140:429029
 TITLE: Otoprotective compositions that treat
 ototoxic side effects of aminoglycoside
 antibiotics and platinum-containing antineoplastic
 agents
 INVENTOR(S): Currie, Mark G.; Heefner, Donald L.
 ; Rubin, Paul; Zepp, Charles M.
 PATENT ASSIGNEE(S): Sepracor, Inc., USA
 SOURCE: PCT Int. Appl., 56 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004043447	A2	20040527	WO 2003-US36269	20031113
WO 2004043447	A3	20050127		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2003299560	A1	20040603	AU 2003-299560	20031113
US 2005101534	A1	20050512	US 2003-712849	20031113
PRIORITY APPLN. INFO.:			US 2002-425878P	P 20021113
			WO 2003-US36269	W 20031113
OTHER SOURCE(S):		MARPAT 140:429029		

L98 ANSWER 2 OF 27 CAPLUS COPYRIGHT 2007 ACS on STN

Gregg Polansky 10/712,849

ACCESSION NUMBER: 1980:15423 CAPLUS Full-text
DOCUMENT NUMBER: 92:15423
TITLE: False precursors of melanin as selective melanoma seekers
AUTHOR(S): Dencker, L.; Larsson, B.; Olander, K.; Ullberg, S.; Yokota, M.
CORPORATE SOURCE: Biomed. Cent., Univ. Uppsala, Uppsala, Swed.
SOURCE: British Journal of Cancer (1979), 39(4), 449-52
CODEN: BJCAAI; ISSN: 0007-0920
DOCUMENT TYPE: Journal
LANGUAGE: English

L98 ANSWER 3 OF 27 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 1976:29503 CAPLUS Full-text
DOCUMENT NUMBER: 84:29503
TITLE: Interrelations between athyreotic and copper-deficient states in rats
AUTHOR(S): Oliver, Jack W.
CORPORATE SOURCE: Coll. Vet. Med., Ohio State Univ., Columbus, OH, USA
SOURCE: American Journal of Veterinary Research (1975), 36(11), 1649-53
CODEN: AJVRAH; ISSN: 0002-9645
DOCUMENT TYPE: Journal
LANGUAGE: English

L98 ANSWER 4 OF 27 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 1966:415571 CAPLUS Full-text
DOCUMENT NUMBER: 65:15571
ORIGINAL REFERENCE NO.: 65:2921c-e
TITLE: Effect of a nucleic acid and its antimetabolites on induction of flowering in winter cereals
AUTHOR(S): Suge, Hiroshi; Yamada, Noboru
CORPORATE SOURCE: Natl. Inst. Agr. Sci., Konosu, Japan
SOURCE: Nippon Sakumotsu Gakkai Kiji (1965), 33(4), 324-9
CODEN: NISAAJ; ISSN: 0011-1848
DOCUMENT TYPE: Journal
LANGUAGE: English

L98 ANSWER 5 OF 27 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 1960:30379 CAPLUS Full-text
DOCUMENT NUMBER: 54:30379
ORIGINAL REFERENCE NO.: 54:5965g-i
TITLE: Thyroid, parathyroid, and calcium salts of the endolymphatic sac in thiouracil-treated larvae of Bufo bufo bufo
AUTHOR(S): Guardabassi, Antonietta
CORPORATE SOURCE: Univ. Turin
SOURCE: Arch. ital. anat. e embriol. (1959), 64, 105-27
DOCUMENT TYPE: Journal
LANGUAGE: Unavailable

L98 ANSWER 6 OF 27 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 1946:5568 CAPLUS Full-text
DOCUMENT NUMBER: 40:5568
ORIGINAL REFERENCE NO.: 40:955a-d
TITLE: Thiouracil in goiter
AUTHOR(S): Cookson, Harold
CORPORATE SOURCE: Cornelia Hosp., Poole, UK
SOURCE: Lancet (1945), 249, 485-9
CODEN: LANCAO; ISSN: 0140-6736

Gregg Polansky 10/712,849

DOCUMENT TYPE: Journal
LANGUAGE: Unavailable

L98 ANSWER 7 OF 27 MEDLINE on STN DUPLICATE 1
ACCESSION NUMBER: 2006432588 MEDLINE Full-text
DOCUMENT NUMBER: PubMed ID: 16855499
TITLE: When is enophthalmos "significant"?.
AUTHOR: Koo Lily; Hatton Mark P; Rubin Peter A D
CORPORATE SOURCE: Ophthalmic Plastics, Orbital, and Aesthetic Surgery,
Massachusetts Eye and Ear Infirmary, Boston, Massachusetts
02114, USA.
SOURCE: Ophthalmic plastic and reconstructive surgery, (2006
Jul-Aug) Vol. 22, No. 4, pp. 274-7.
Journal code: 8508431. ISSN: 0740-9303.
PUB. COUNTRY: United States
DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)
LANGUAGE: English
FILE SEGMENT: Priority Journals
ENTRY MONTH: 200608
ENTRY DATE: Entered STN: 21 Jul 2006
Last Updated on STN: 17 Aug 2006
Entered Medline: 16 Aug 2006

L98 ANSWER 8 OF 27 MEDLINE on STN DUPLICATE 2
ACCESSION NUMBER: 2005110437 MEDLINE Full-text
DOCUMENT NUMBER: PubMed ID: 15558295
TITLE: The clinicopathological spectrum of benign peripunctal
tumours.
AUTHOR: Rumelt Shimon; Pe'er Jacob; Rubin Peter A D
CORPORATE SOURCE: Department of Ophthalmology, Hadassah University Hospital,
Jerusalem, Israel.
SOURCE: Graefe's archive for clinical and experimental
ophthalmology = Albrecht von Graefes Archiv fur klinische
und experimentelle Ophthalmologie, (2005 Feb) Vol. 243, No.
2, pp. 113-9. Electronic Publication: 2004-11-19.
Journal code: 8205248. ISSN: 0721-832X.
PUB. COUNTRY: Germany: Germany, Federal Republic of
DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)
LANGUAGE: English
FILE SEGMENT: Priority Journals
ENTRY MONTH: 200504
ENTRY DATE: Entered STN: 3 Mar 2005
Last Updated on STN: 26 Apr 2005
Entered Medline: 25 Apr 2005

L98 ANSWER 9 OF 27 MEDLINE on STN DUPLICATE 4
ACCESSION NUMBER: 2003124162 MEDLINE Full-text
DOCUMENT NUMBER: PubMed ID: 12623823
TITLE: Bilateral cavernous sinus thromboses and intraorbital
abscesses secondary to Streptococcus milleri.
AUTHOR: Watkins Lynnette M; Pasternack Mark S; Banks Michelle;
Kousoubris Philip; Rubin Peter A D
CORPORATE SOURCE: Ophthalmic Plastic, Orbital, Reconstructive and Cosmetic
Surgery Service, Massachusetts Eye and Ear Infirmary,
Harvard Medical School, 243 Charles Street, Boston, MA
02114, USA.
SOURCE: Ophthalmology, (2003 Mar) Vol. 110, No. 3, pp. 569-74.
Journal code: 7802443. ISSN: 0161-6420.
PUB. COUNTRY: United States
DOCUMENT TYPE: (CASE REPORTS)

Gregg Polansky 10/712,849

Journal; Article; (JOURNAL ARTICLE)
 LANGUAGE: English
 FILE SEGMENT: Priority Journals
 ENTRY MONTH: 200303
 ENTRY DATE: Entered STN: 18 Mar 2003
 Last Updated on STN: 25 Mar 2003
 Entered Medline: 24 Mar 2003

L98 ANSWER 10 OF 27 MEDLINE on STN DUPLICATE 5
 ACCESSION NUMBER: 2001315737 MEDLINE Full-text
 DOCUMENT NUMBER: PubMed ID: 11388382
 TITLE: Orbital fractures in children.
 AUTHOR: Hatton M P; Watkins L M; Rubin P A
 CORPORATE SOURCE: Massachusetts Eye and Ear Infirmary, Boston, Massachusetts 02114, USA.
 SOURCE: Ophthalmic plastic and reconstructive surgery, (2001 May) Vol. 17, No. 3, pp. 174-9.
 Journal code: 8508431. ISSN: 0740-9303.
 PUB. COUNTRY: United States
 DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)
 LANGUAGE: English
 FILE SEGMENT: Priority Journals
 ENTRY MONTH: 200110
 ENTRY DATE: Entered STN: 8 Oct 2001
 Last Updated on STN: 8 Oct 2001
 Entered Medline: 4 Oct 2001

L98 ANSWER 11 OF 27 MEDLINE on STN DUPLICATE 6
 ACCESSION NUMBER: 1998254230 MEDLINE Full-text
 DOCUMENT NUMBER: PubMed ID: 9593398
 TITLE: Enhancement of the cosmetic and functional outcome of enucleation with the conical orbital implant.
 AUTHOR: Rubin P A; Popham J; Rumelt S; Remulla H; Bilyk J R; Holds J; Mannor G; Maus M; Patrinely J R
 CORPORATE SOURCE: Ophthalmic Plastics, Orbital, and Cosmetic Eyelid Surgery, Massachusetts Eye and Ear Infirmary, Boston 02114, USA.
 SOURCE: Ophthalmology, (1998 May) Vol. 105, No. 5, pp. 919-25.
 Journal code: 7802443. ISSN: 0161-6420.
 PUB. COUNTRY: United States
 DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)
 LANGUAGE: English
 FILE SEGMENT: Priority Journals
 ENTRY MONTH: 199805
 ENTRY DATE: Entered STN: 29 May 1998
 Last Updated on STN: 29 May 1998
 Entered Medline: 21 May 1998

L98 ANSWER 12 OF 27 MEDLINE on STN DUPLICATE 7
 ACCESSION NUMBER: 97452852 MEDLINE Full-text
 DOCUMENT NUMBER: PubMed ID: 9307642
 TITLE: Orbital venous anomalies demonstrated by spiral computed tomography.
 AUTHOR: Rubin P A; Remulla H D
 CORPORATE SOURCE: Department of Ophthalmology Massachusetts Eye and Ear Infirmary, Harvard Medical School, Boston, USA.
 SOURCE: Ophthalmology, (1997 Sep) Vol. 104, No. 9, pp. 1463-70.
 Journal code: 7802443. ISSN: 0161-6420.
 PUB. COUNTRY: United States
 DOCUMENT TYPE: (CASE REPORTS)
 Journal; Article; (JOURNAL ARTICLE)

LANGUAGE: English
 FILE SEGMENT: Priority Journals
 ENTRY MONTH: 199710
 ENTRY DATE: Entered STN: 13 Oct 1997
 Last Updated on STN: 13 Oct 1997
 Entered Medline: 2 Oct 1997

L98 ANSWER 13 OF 27 MEDLINE on STN
 ACCESSION NUMBER: 2007436310 MEDLINE Full-text
 DOCUMENT NUMBER: PubMed ID: 17648453
 TITLE: Surgery for the Relief or Correction of Disease of the
 Ear of the Dog and Cat.
 AUTHOR: Zepp C P
 SOURCE: Canadian journal of comparative medicine and veterinary
 science, (1950 Jan) Vol. 14, No. 1, pp. 19-21.
 Journal code: 0151757. ISSN: 0316-5957.
 PUB. COUNTRY: Canada
 DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)
 LANGUAGE: English
 FILE SEGMENT: NONMEDLINE; PUBMED-NOT-MEDLINE
 ENTRY MONTH: 200707
 ENTRY DATE: Entered STN: 28 Jul 2007
 Last Updated on STN: 28 Jul 2007
 Entered Medline: 27 Jul 2007

L98 ANSWER 14 OF 27 MEDLINE on STN
 ACCESSION NUMBER: 2007436309 MEDLINE Full-text
 DOCUMENT NUMBER: PubMed ID: 17648452
 TITLE: Ear Diseases of the Dog and Cat.
 AUTHOR: Zepp C P
 SOURCE: Canadian journal of comparative medicine and veterinary
 science, (1950 Jan) Vol. 14, No. 1, pp. 15-9.
 Journal code: 0151757. ISSN: 0316-5957.
 PUB. COUNTRY: Canada
 DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)
 LANGUAGE: English
 FILE SEGMENT: NONMEDLINE; PUBMED-NOT-MEDLINE
 ENTRY MONTH: 200707
 ENTRY DATE: Entered STN: 28 Jul 2007
 Last Updated on STN: 28 Jul 2007
 Entered Medline: 27 Jul 2007

L98 ANSWER 15 OF 27 EMBASE COPYRIGHT (c) 2007 Elsevier B.V. All rights
 reserved on STN
 ACCESSION NUMBER: 2006346540 EMBASE Full-text
 TITLE: Role of inflammation in orbital cellulitis.
 AUTHOR: Kloek C.E.; Rubin P.A.D.
 CORPORATE SOURCE: Dr. C.E. Kloek, Massachusetts Eye and Ear Infirmary, 243
 Charles Street, Boston, MA 02114, United States
 SOURCE: International Ophthalmology Clinics, (2006) Vol. 46, No. 2,
 pp. 57-68. .
 Refs: 41
 ISSN: 0020-8167 CODEN: IOPCAV
 PUBLISHER IDENT.: 0000439720060462000007
 COUNTRY: United States
 DOCUMENT TYPE: Journal; Conference Article
 FILE SEGMENT: 012 Ophthalmology
 037 Drug Literature Index
 038 Adverse Reactions Titles
 LANGUAGE: English

SUMMARY LANGUAGE: English
 ENTRY DATE: Entered STN: 18 Aug 2006
 Last Updated on STN: 18 Aug 2006

L98 ANSWER 16 OF 27 EMBASE COPYRIGHT (c) 2007 Elsevier B.V. All rights reserved on STN

ACCESSION NUMBER: 2003045694 EMBASE Full-text
 TITLE: Medial rectus muscle injuries associated with functional endoscopic sinus surgery: Characterization and management.
 AUTHOR: Huang C.M.; Meyer D.R.; Patrinely J.R.; Soparkar C.N.S.; Dailey R.A.; Maus M.; Rubin P.A.D.; Patrick Yeatts R.; Bersani T.A.; Karesh J.W.; Harrison A.R.; Shovlin J.P.
 CORPORATE SOURCE: Dr. D.R. Meyer, Lions Eye Institute, Albany Medical Center, 35 Hackett Blvd., Albany, NY 12208, United States. meyerd@mail.amc.edu
 SOURCE: Ophthalmic Plastic and Reconstructive Surgery, (2003) Vol. 19, No. 1, pp. 25-37. . Refs: 37
 ISSN: 0740-9303 CODEN: OPRSEU
 COUNTRY: United States
 DOCUMENT TYPE: Journal; Article
 FILE SEGMENT: 011 Otorhinolaryngology
 012 Ophthalmology
 LANGUAGE: English
 SUMMARY LANGUAGE: English
 ENTRY DATE: Entered STN: 7 Feb 2003
 Last Updated on STN: 7 Feb 2003

L98 ANSWER 17 OF 27 EMBASE COPYRIGHT (c) 2007 Elsevier B.V. All rights reserved on STN

ACCESSION NUMBER: 93307672 EMBASE Full-text
 DOCUMENT NUMBER: 1993307672
 TITLE: On the intonation of sinusoidal sentences: Contour and pitch height.
 AUTHOR: Remez R.E.; Rubin P.E.
 CORPORATE SOURCE: Department of Psychology, Barnard College, 3009 Broadway, New York, NY 10027-6598, United States
 SOURCE: Journal of the Acoustical Society of America, (1993) Vol. 94, No. 4, pp. 1983-1988. . ISSN: 0001-4966 CODEN: JASMAN
 COUNTRY: United States
 DOCUMENT TYPE: Journal; Article
 FILE SEGMENT: 011 Otorhinolaryngology
 027 Biophysics, Bioengineering and Medical Instrumentation
 LANGUAGE: English
 SUMMARY LANGUAGE: English
 ENTRY DATE: Entered STN: 14 Nov 1993
 Last Updated on STN: 14 Nov 1993

L98 ANSWER 18 OF 27 EMBASE COPYRIGHT (c) 2007 Elsevier B.V. All rights reserved on STN

ACCESSION NUMBER: 91026329 EMBASE Full-text
 DOCUMENT NUMBER: 1991026329
 TITLE: A request for an abortion.
 AUTHOR: Walker A.; Marsden S.; Rubin P.
 CORPORATE SOURCE: University Hospital, Nottingham, United Kingdom
 SOURCE: Practitioner, (1990) Vol. 234, No. 1497, pp. 1013-1016. . ISSN: 0032-6518 CODEN: PRACAK

COUNTRY: United Kingdom
DOCUMENT TYPE: Journal; Article
FILE SEGMENT: 010 Obstetrics and Gynecology
011 Otorhinolaryngology
037 Drug Literature Index
038 Adverse Reactions Titles
LANGUAGE: English
ENTRY DATE: Entered STN: 16 Dec 1991
Last Updated on STN: 16 Dec 1991

L98 ANSWER 19 OF 27 EMBASE COPYRIGHT (c) 2007 Elsevier B.V. All rights reserved on STN

ACCESSION NUMBER: 90144580 EMBASE Full-text
DOCUMENT NUMBER: 1990144580
TITLE: Childhood otalgia: Acute otitis media. 1.
Antibiotics not necessary in most cases: Editorial comment.
AUTHOR: Rubin P.C.
CORPORATE SOURCE: University of Nottingham, Nottingham, United Kingdom
SOURCE: British Medical Journal, (1990) Vol. 300, No. 6730, pp. 1005. .
ISSN: 0959-8146 CODEN: BMJOAE

COUNTRY: United Kingdom
DOCUMENT TYPE: Journal; Note
FILE SEGMENT: 007 Pediatrics and Pediatric Surgery
011 Otorhinolaryngology
037 Drug Literature Index
LANGUAGE: English
ENTRY DATE: Entered STN: 13 Dec 1991
Last Updated on STN: 13 Dec 1991

L98 ANSWER 20 OF 27 EMBASE COPYRIGHT (c) 2007 Elsevier B.V. All rights reserved on STN

ACCESSION NUMBER: 78180793 EMBASE Full-text
DOCUMENT NUMBER: 1978180793
TITLE: Mosaic trisomy 9: Two additional cases.
AUTHOR: Tropp M.R.; Currie M.
CORPORATE SOURCE: Pathol. Dept., Roy. Child. Hosp., Melbourne, Australia
SOURCE: Human Genetics, (1977) Vol. 38, No. 2, pp. 131-135. .
CODEN: HUGEDQ
COUNTRY: Germany
DOCUMENT TYPE: Journal
FILE SEGMENT: 022 Human Genetics
007 Pediatrics and Pediatric Surgery
LANGUAGE: English

L98 ANSWER 21 OF 27 WPIX COPYRIGHT 2007 THE THOMSON CORP on STN
ACCESSION NUMBER: 2006-569520 [58] WPIX
CROSS REFERENCE: 2005-173214
DOC. NO. CPI: C2006-177026 [58]
TITLE: Novel purified polypeptide that activates guanylate cyclase C receptor, useful for treating diseases e.g. gastrointestinal disorders, obesity or congestive heart failure
DERWENT CLASS: B04
INVENTOR: CURRIE M G; KURTZ C; MAHAJAN-MIKLOS S; SUN L J
PATENT ASSIGNEE: (MICR-N) MICROBIA INC
COUNTRY COUNT: 111

PATENT INFO ABBR.:

Gregg Polansky 10/712,849

PATENT NO	KIND	DATE	WEEK	LA	PG	MAIN IPC
WO 2006086653	A2	20060817	(200658)*	EN	409[3]	

APPLICATION DETAILS:

PATENT NO	KIND	APPLICATION	DATE
WO 2006086653	A2	WO 2006-US4768	20060208

PRIORITY APPLN. INFO: US 2005-54072 20050208

L98 ANSWER 22 OF 27 WPIX COPYRIGHT 2007 THE THOMSON CORP on STN
 ACCESSION NUMBER: 2005-582766 [59] WPIX
 DOC. NO. CPI: C2005-175823 [59]
 TITLE: Use of composition comprising chymotrypsin inhibitor in the treatment of patient suffering from or at risk for congestive heart failure, prostatic hyperplasia, gastrointestinal disorder; obesity; and for decreasing gastrointestinal pain
 DERWENT CLASS: B05
 INVENTOR: CURRIE M G
 PATENT ASSIGNEE: (MICR-N) MICROBIA INC
 COUNTRY COUNT: 106

PATENT INFO ABBR.:

PATENT NO	KIND	DATE	WEEK	LA	PG	MAIN IPC
WO 2005074575	A2	20050818	(200559)*	EN	207[5]	

APPLICATION DETAILS:

PATENT NO	KIND	APPLICATION	DATE
WO 2005074575	A2	WO 2005-US2941	20050131

PRIORITY APPLN. INFO: US 2004-540675P 20040130

L98 ANSWER 23 OF 27 WPIX COPYRIGHT 2007 THE THOMSON CORP on STN
 ACCESSION NUMBER: 2004-604332 [58] WPIX
 CROSS REFERENCE: 2005-639160
 DOC. NO. CPI: C2004-218947; C2006-063571 [58] [20]
 TITLE: Novel purified peptide capable of activating the guanylate cyclase C receptor, useful for treating obesity, congestive heart failure and benign prostatic hyperplasia
 DERWENT CLASS: B04; B05; D16
 INVENTOR: CURRIE M G; MAHAJAN M S; MAHAJAN-MIKLOS S; MILNE G T; MILNE T G; NORMAN T; THEA N; CURRIE M
 PATENT ASSIGNEE: (CURR-I) CURRIE M G; (MAHA-I) MAHAJAN-MIKLOS S; (MICR-N) MICROBIA INC
 COUNTRY COUNT: 107

PATENT INFO ABBR.:

PATENT NO	KIND	DATE	WEEK	LA	PG	MAIN IPC
WO 2004069165	A2	20040819	(200458)*	EN	93[10]	
US 20040266989	A1	20041230	(200503)	EN		

Gregg Polansky 10/712,849

US 20050020811	A1	20050127	(200509)	EN	
AU 2004210161	A1	20040819	(200562)	EN	
EP 1594517	A2	20051116	(200575)	EN	
BR 2004007071	A	20060124	(200611)	PT	
NO 2005003864	A	20051026	(200622)	NO	1[0]
MX 2005008097	A1	20060201	(200643)	ES	
JP 2006516631	W	20060706	(200645)	JA	63
KR 2005106404	A	20051109	(200667)	KO	
CN 1795007	A	20060628	(200672)	ZH	
ZA 2005006714	A	20061129	(200703)	EN	106
EP 1594517	B1	20070620	(200741)	EN	
IN 2005DN03394	P1	20070601	(200748)	EN	

APPLICATION DETAILS:

PATENT NO	KIND	APPLICATION	DATE
WO 2004069165	A2	WO 2004-US2390	20040128
US 20040266989	A1 Provisional	US 2003-443098P	20030128
US 20050020811	A1 Provisional	US 2003-443098P	20030128
US 20040266989	A1 Provisional	US 2003-471288P	20030515
US 20050020811	A1 Provisional	US 2003-471288P	20030515
US 20040266989	A1 Provisional	US 2003-519460P	20031112
US 20050020811	A1 Provisional	US 2003-519460P	20031112
AU 2004210161	A1	AU 2004-210161	20040128
BR 2004007071	A	BR 2004-7071	20040128
CN 1795007	A	CN 2004-80008533	20040128
EP 1594517	A2	EP 2004-706011	20040128
EP 1594517	B1	EP 2004-706011	20040128
US 20040266989	A1	US 2004-766735	20040128
US 20050020811	A1 CIP of	US 2004-766735	20040128
EP 1594517	A2	WO 2004-US2390	20040128
BR 2004007071	A	WO 2004-US2390	20040128
MX 2005008097	A1	WO 2004-US2390	20040128
JP 2006516631	W	WO 2004-US2390	20040128
KR 2005106404	A	WO 2004-US2390	20040128
EP 1594517	B1	WO 2004-US2390	20040128
US 20050020811	A1	US 2004-796719	20040309
ZA 2005006714	A	ZA 2005-6714	20040128
KR 2005106404	A	KR 2005-713966	20050728
MX 2005008097	A1	MX 2005-8097	20050728
NO 2005003864	A	NO 2005-3864	20050818
JP 2006516631	W	JP 2006-503109	20040128
IN 2005003394	P1	WO 2004-US2390	20040128
IN 2005003394	P1	IN 2005-DN3394	20050801

FILING DETAILS:

PATENT NO	KIND	PATENT NO
AU 2004210161	A1 Based on	WO 2004069165 A
EP 1594517	A2 Based on	WO 2004069165 A
BR 2004007071	A Based on	WO 2004069165 A
MX 2005008097	A1 Based on	WO 2004069165 A
JP 2006516631	W Based on	WO 2004069165 A
KR 2005106404	A Based on	WO 2004069165 A
EP 1594517	B1 Based on	WO 2004069165 A

PRIORITY APPLN. INFO: US 2003-519460P 20031112
US 2003-443098P 20030128

Gregg Polansky 10/712,849

US 2003-471288P 20030515
US 2004-766735 20040128
US 2004-796719 20040309

L98 ANSWER 24 OF 27 WPIX COPYRIGHT 2007 THE THOMSON CORP on STN
ACCESSION NUMBER: 2000-579216 [54] WPIX
CROSS REFERENCE: 2000-587227; 2001-565399
DOC. NO. CPI: C2000-172404 [54]
TITLE: Method for treating neuropathic pain, including central
and peripheral neuropathy, and tinnitus
comprises administration of R(-)-ketoprofen
B05
DERWENT CLASS:
INVENTOR: JERUSSI T P; RUBIN P D
PATENT ASSIGNEE: (SEPR-N) SEPRACOR INC
COUNTRY COUNT: 89

PATENT INFO ABBR.:

PATENT NO	KIND	DATE	WEEK	LA	PG	MAIN IPC
WO 2000051595	A1	20000908	(200054)*	EN	26[0]	
AU 2000037111	A	20000921	(200065)	EN		
EP 1156794	A1	20011128	(200201)	EN		
US 6362227	B1	20020326	(200226)	EN		
US 20020147238	A1	20021010	(200269)	EN		
JP 2003520193	W	20030702	(200352)	JA	31	
US 6620851	B2	20030916	(200362)	EN		
US 20040019111	A1	20040129	(200413)	EN		

APPLICATION DETAILS:

PATENT NO	KIND	APPLICATION	DATE
WO 2000051595	A1	WO 2000-US5170	20000301
US 6362227	B1 Provisional	US 1999-122382P	19990302
US 20020147238	A1 Provisional	US 1999-122382P	19990302
US 6620851	B2 Provisional	US 1999-122382P	19990302
US 20040019111	A1 Provisional	US 1999-122382P	19990302
US 6362227	B1	US 2000-507470	20000222
US 20020147238	A1 Div Ex	US 2000-507470	20000222
US 6620851	B2 Div Ex	US 2000-507470	20000222
US 20040019111	A1 Div Ex	US 2000-507470	20000222
AU 2000037111	A	AU 2000-37111	20000301
EP 1156794	A1	EP 2000-915921	20000301
JP 2003520193	W	JP 2000-602063	20000301
EP 1156794	A1	WO 2000-US5170	20000301
JP 2003520193	W	WO 2000-US5170	20000301
US 20020147238	A1	US 2002-62766	20020205
US 6620851	B2	US 2002-62766	20020205
US 20040019111	A1 Div Ex	US 2002-62766	20020205
US 20040019111	A1	US 2003-620704	20030717

FILING DETAILS:

PATENT NO	KIND	PATENT NO
US 20020147238	A1 Div ex	US 6362227 B
US 6620851	B2 Div ex	US 6362227 B
US 20040019111	A1 Div ex	US 6362227 B
US 20040019111	A1 Div ex	US 6620851 B

Gregg Polansky 10/712,849

AU 2000037111 A	Based on	WO 2000051595 A
EP 1156794 A1	Based on	WO 2000051595 A
JP 2003520193 W	Based on	WO 2000051595 A

PRIORITY APPLN. INFO: US 2000-507470 20000222
 US 1999-122382P 19990302
 US 2002-62766 20020205
 US 2003-620704 20030717

L98 ANSWER 25 OF 27 WPIX COPYRIGHT 2007 THE THOMSON CORP on STN
 ACCESSION NUMBER: 2000-431259 [37] WPIX
 CROSS REFERENCE: 1999-095304; 1999-095313; 2001-181513; 2002-453150
 DOC. NO. CPI: C2000-131036 [37]
 TITLE: New quinoline-indole compounds, useful for treating bacterial infections, particularly antibiotic resistant infections, or for inhibiting microbial growth in tissue culture
 DERWENT CLASS: B02; B04; C02; D16
 INVENTOR: CUNY G D; HAUSKE J R; HEEFNER D L; HOEMANN M Z; KUMARAVEL G; MELIKIAN-BADALIAN A; ROSSI R F; XIE R L
 PATENT ASSIGNEE: (SEPR-N) SEPRACOR INC
 COUNTRY COUNT: 88

PATENT INFO ABBR.:

PATENT NO	KIND	DATE	WEEK	LA	PG	MAIN IPC
WO 2000034265	A2	20000615	(200037)*	EN	154[0]	
US 6103905	A	20000815	(200041)	EN		
AU 2000019335	A	20000626	(200045)	EN		

APPLICATION DETAILS:

PATENT NO	KIND	APPLICATION	DATE
WO 2000034265	A2	WO 1999-US28744	19991203
US 6103905	A CIP of	US 1997-878781	19970619
US 6103905	A CIP of	US 1998-45051	19980319
US 6103905	A CIP of	US 1998-99640	19980618
US 6103905	A	US 1998-213385	19981211
AU 2000019335	A	AU 2000-19335	19991203

FILING DETAILS:

PATENT NO	KIND	PATENT NO
AU 2000019335	A	WO 2000034265
	Based on	A

PRIORITY APPLN. INFO: US 1998-213385 19981211
 US 1997-878781 19970619
 US 1998-45051 19980319
 US 1998-99640 19980618

L98 ANSWER 26 OF 27 WPIX COPYRIGHT 2007 THE THOMSON CORP on STN
 ACCESSION NUMBER: 1999-095313 [08] WPIX
 CROSS REFERENCE: 1999-095304; 2000-431259; 2001-181513; 2002-453150
 DOC. NO. CPI: C1999-028059 [08]
 TITLE: New isoquinoline-indole derivatives - used for treating bacterial infection and are active against Gram positive and Gram negative bacteria, including multiply resistant

Gregg Polansky 10/712,849

strains
 DERWENT CLASS: B05
 INVENTOR: CUNY G D; HAUSKE J R; HEEFNER D L; HOEMANN M Z;
 KUMARAVEL G; MELIKIAN-BADALIAN A; ROSSI R F
 PATENT ASSIGNEE: (SEPR-N) SEPRACOR INC
 COUNTRY COUNT: 80

PATENT INFO ABBR.:

PATENT NO	KIND	DATE	WEEK	LA	PG	MAIN IPC
WO 9857952	A1	19981223	(199908)*	EN	137	[0]
AU 9882586	A	19990104	(199921)	EN		

APPLICATION DETAILS:

PATENT NO	KIND	APPLICATION	DATE
WO 9857952	A1	WO 1998-US12706	19980618
AU 9882586	A	AU 1998-82586	19980618

FILING DETAILS:

PATENT NO	KIND	PATENT NO
AU 9882586	A	Based on
		WO 9857952

PRIORITY APPLN. INFO: US 1997-878781 19970619.

L98 ANSWER 27 OF 27 WPIX COPYRIGHT 2007 THE THOMSON CORP on STN
 ACCESSION NUMBER: 1999-095304 [08] WPIX
 CROSS REFERENCE: 1999-095313; 2000-431259; 2001-181513; 2002-453150
 DOC. NO. CPI: C1999-028050 [08]
 TITLE: New 2-(Indol-3-yl)quinoline compounds - active against
 Gram positive and Gram negative bacteria, including
 multiply resistant strains
 DERWENT CLASS: B02; B05
 INVENTOR: CUNY G D; HAUSKE J R; HEEFNER D L; HOEMANN M Z;
 KUMARAVEL G; MELIKIAN-BADALIAN A; ROSSI R F
 PATENT ASSIGNEE: (SEPR-N) SEPRACOR INC
 COUNTRY COUNT: 81

PATENT INFO ABBR.:

PATENT NO	KIND	DATE	WEEK	LA	PG	MAIN IPC
WO 9857931	A2	19981223	(199908)*	EN	145	[0]
AU 9879797	A	19990104	(199921)	EN		
NO 9906269	A	20000216	(200020)	NO		
EP 991623	A2	20000412	(200023)	EN		
CZ 9904608	A3	20000816	(200048)	CS		
US 6207679	B1	20010327	(200119)	EN		
HU 2000003364	A2	20010628	(200143)	HU		
KR 2001014030	A	20010226	(200154)	KO		
JP 2002505689	W	20020219	(200216)	JA	189	
AU 757059	B	20030130	(200319)	EN		

APPLICATION DETAILS:

PATENT NO	KIND	APPLICATION	DATE
-----------	------	-------------	------

WO 9857931 A2	WO 1998-US12762 19980618
US 6207679 B1 CIP of	US 1997-878781 19970619
US 6207679 B1	US 1998-45051 19980319
AU 9879797 A	AU 1998-79797 19980618
AU 757059 B	AU 1998-79797 19980618
EP 991623 A2	EP 1998-930396 19980618
NO 9906269 A	WO 1998-US12762 19980618
EP 991623 A2	WO 1998-US12762 19980618
CZ 9904608 A3	WO 1998-US12762 19980618
HU 2000003364 A2	WO 1998-US12762 19980618
JP 2002505689 W	WO 1998-US12762 19980618
CZ 9904608 A3	CZ 1999-4608 19980618
JP 2002505689 W	JP 1999-504835 19980618
NO 9906269 A	NO 1999-6269 19991217
KR 2001014030 A	KR 1999-712059 19991220
HU 2000003364 A2	HU 2000-3364 19980618

FILING DETAILS:

PATENT NO	KIND	PATENT NO
AU 757059 B	Previous Publ	AU 9879797 A
AU 9879797 A	Based on	WO 9857931 A
EP 991623 A2	Based on	WO 9857931 A
CZ 9904608 A3	Based on	WO 9857931 A
HU 2000003364 A2	Based on	WO 9857931 A
JP 2002505689 W	Based on	WO 9857931 A
AU 757059 B	Based on	WO 9857931 A

PRIORITY APPLN. INFO: US 1998-45051 19980319
US 1997-878781 19970619

=> fil caplus medline biosis embase
FILE 'CAPLUS' ENTERED AT 13:43:33 ON 20 AUG 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'MEDLINE' ENTERED AT 13:43:33 ON 20 AUG 2007

FILE 'BIOSIS' ENTERED AT 13:43:33 ON 20 AUG 2007
Copyright (c) 2007 The Thomson Corporation

FILE 'EMBASE' ENTERED AT 13:43:33 ON 20 AUG 2007
Copyright (c) 2007 Elsevier B.V. All rights reserved.

=> d que nos
L105 54949 SEA HEARING (2A) LOSS
L107 17784 SEA PYRIMIDINE## (3A) DERIV?
L108 2 SEA L105 AND L107

=> d ibib ab ct 1-2 1108

L108 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2007:438159 CAPLUS Full-text
DOCUMENT NUMBER: 146:441811
TITLE: Preparation of novel pyrimidine-2,4-diamine

derivatives and their use as modulators of
small-conductance calcium-activated potassium channels

INVENTOR(S): Soerensen, Ulrik Svane; Eriksen, Birgitte L.; Teuber, Lene; Peters, Dan; Stroeback, Dorte; Johansen, Tina Holm; Christophersen, Palle

PATENT ASSIGNEE(S): Neurosearch A/S, Den.

SOURCE: PCT Int. Appl., 29pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2007042571	A1	20070419	WO 2006-EP67387	20061013
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				

PRIORITY APPLN. INFO.: DK 2005-1439 A 20051014
US 2005-726508P P 20051014

OTHER SOURCE(S): MARPAT 146:441811

AB This invention relates to novel pyrimidine-2,4-diamine derivs. I [R1 = (CH2)vR5 (wherein v = 0 or 1; R5 = (un)substituted aryl); R11, R111 = H or (un)substituted alkyl; or R11 together with R111 form (CH2)p (p = 3-5); or R11 forms a (CH2)q bridge to an ortho position of the aryl group of R1 (q = 2-4) and R111 = H or (un)substituted alkyl; R2 = (CH2)wR6 (w = 0-1; R6 = (un)substituted aryl); R22, R222 = H or (un)substituted alkyl; or R22 together with R222 form (CH2)s (s = 3-5); or R22 forms a (CH2)t bridge to an ortho position of the aryl group of R2 (t = 2-4) and R222 = H or (un)substituted alkyl; R3, R4 = H, halo, CF3, etc.], useful as modulators of small-conductance calcium-activated potassium channels (SK channels). Fourteen compds. I were prepared. Thus, reacting 2,4-dichloropyrimidine with 3,4-difluorobenzylamine afforded N2,N4-bis(3,4-difluorobenzyl)pyrimidine-2,4-diamine. In other aspects the invention relates to the use of the compds. I in a method for therapy and to pharmaceutical compns. comprising the compds. I.

CT Blood vessel, disease

CT Amnesia

CT Nervous system, disease

CT Mental and behavioral disorders

CT Mental and behavioral disorders

CT Bladder, disease

CT Bladder, disease

CT Potassium channel

CT Drug delivery systems

CT Embolism

CT Ischemia

CT Lung, disease

CT Inflammation

CT Intestine, disease

CT Intestine, disease

CT Mental and behavioral disorders
 CT Mental and behavioral disorders
 CT Gastrointestinal motility
 CT Gastrointestinal motility
 CT Digestive tract, disease
 CT Intestine, disease
 CT Sexual disorders
 CT Bladder, disease
 CT Pain
 CT Intestine, disease
 CT Artery, disease
 CT Intestine, disease
 CT Brain, disease
 CT Memory disorders
 CT Headache
 CT Mental and behavioral disorders
 CT Nerve, disease
 CT Neuromuscular diseases
 CT Muscular dystrophy
 CT Muscular dystrophy
 CT Pain
 CT Diabetes mellitus
 CT Bladder, disease
 CT Epilepsy
 CT Drug delivery systems
 CT Kidney, disease
 CT Parturition disorders
 CT Aging, animal
 CT Alopecia
 CT Alzheimer's disease
 CT Analgesics
 CT Angina pectoris
 CT Anti-Alzheimer's agents
 CT Anti-inflammatory agents
 CT Anti-ischemic agents
 CT Antianginal agents
 CT Antiarrhythmics
 CT Antiasthmatics
 CT Anticonvulsants
 CT Antidepressants
 CT Antidiabetic agents
 CT Antidiarrheals
 CT Antifibrotic agents
 CT Antihypertensives
 CT Antimigraine agents
 CT Antiparkinsonian agents
 CT Antipsychotics
 CT Antitumor agents
 CT Anxiety
 CT Anxiolytics
 CT Asthma
 CT Brain, neoplasm
 CT Cardiac arrhythmia
 CT Cardiovascular agents
 CT Cardiovascular system, disease
 CT Cognition enhancers
 CT Cognitive disorders
 CT Convulsion
 CT Coronary artery disease
 CT Coronary spasm

CT Cystic fibrosis
 CT Digestive tract, disease
 CT Dysmenorrhea
 CT Epilepsy
 CT Gastrointestinal agents
 CT Hearing loss
 CT Human
 CT Hypertension
 CT Immunostimulants
 CT Immunosuppression
 CT Ischemia
 CT Kidney, disease
 CT Laxatives
 CT Learning disorders
 CT Myocardial ischemia
 CT Narcolepsy
 CT Neoplasm
 CT Nervous system agents
 CT Pain
 CT Parkinson's disease
 CT Prophylaxis
 CT Seizures
 CT Sjogren syndrome
 CT Sleep apnea
 CT Sleep disorders
 CT Tocolytic agents
 CT Urogenital system, disease
 CT Mental and behavioral disorders
 CT Nose, disease
 CT Diarrhea
 CT Blood vessel, disease
 CT Nervous system, disease
 CT Brain, disease
 CT Brain, disease
 CT Nerve, disease
 CT Pain
 CT Vision disorders
 CT Mouth, disease

REFERENCE COUNT: 14 THERE ARE 14 CITED REFERENCES AVAILABLE FOR THIS
 RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L108 ANSWER 2 OF 2 EMBASE COPYRIGHT (c) 2007 Elsevier B.V. All rights
 reserved on STN

ACCESSION NUMBER: 2002220093 EMBASE Full-text
 TITLE: Gemcitabine plus cisplatin for the treatment of metastatic
 breast cancer.
 AUTHOR: Heinemann V.
 CORPORATE SOURCE: Dr. V. Heinemann, Medical Clinic III, Klinikum Grosshadern,
 Marchionini St 15, 81377 Munich, Germany.
 volker.heinemann@med3.uni-muenchen.de
 SOURCE: Clinical Breast Cancer, (2002) Vol. 3, No. SUPPL. 1, pp.
 S24-S29. .
 Refs: 30
 ISSN: 1526-8209 CODEN: CBCLB7
 COUNTRY: United States
 DOCUMENT TYPE: Journal; Article
 FILE SEGMENT: 016 Cancer
 030 Pharmacology
 037 Drug Literature Index
 038 Adverse Reactions Titles

LANGUAGE: English
 SUMMARY LANGUAGE: English
 ENTRY DATE: Entered STN: 11 Jul 2002
 Last Updated on STN: 11 Jul 2002

AB The combination of gemcitabine and cisplatin has proven effective as first-line chemotherapy for patients with breast cancer, inducing a response rate of 80% in one phase II study. Five additional studies in intensively pretreated breast cancer patients demonstrated a median response rate of 43% (range, 26%-50%). The toxicity profile was moderate, with thrombocytopenia and neutropenia as the main side effects. The gemcitabine/cisplatin combination, therefore, offers a tolerable and effective treatment option, particularly for patients whose disease progressed after treatment with anthracyclines and/or taxanes.

CT Medical Descriptors:
 *breast cancer: DT, drug therapy
 drug efficacy
 cancer combination chemotherapy
 drug response
 thrombocytopenia: SI, side effect
 neutropenia: SI, side effect
 drug tolerability
 cancer growth
 cardiotoxicity: SI, side effect
 dose response
 antineoplastic activity
 drug effect
 nephrotoxicity: SI, side effect
 peripheral neuropathy: SI, side effect
 hearing loss: SI, side effect
 drug resistance
 neurotoxicity: SI, side effect
 bone marrow toxicity: SI, side effect
 metastasis potential
 human
 female
 clinical trial
 phase 2 clinical trial
 controlled study
 article
 Drug Descriptors:
 *gemcitabine: AE, adverse drug reaction
 *gemcitabine: CT, clinical trial
 *gemcitabine: CB, drug combination
 *gemcitabine: CM, drug comparison
 *gemcitabine: DO, drug dose
 *gemcitabine: IT, drug interaction
 *gemcitabine: DT, drug therapy
 *gemcitabine: PD, pharmacology
 *cisplatin: AE, adverse drug reaction
 *cisplatin: CT, clinical trial
 *cisplatin: CB, drug combination
 *cisplatin: CM, drug comparison
 *cisplatin: DO, drug dose
 *cisplatin: IT, drug interaction
 *cisplatin: DT, drug therapy
 *cisplatin: PD, pharmacology
 anthracycline derivative: AE, adverse drug reaction
 anthracycline derivative: CB, drug combination
 anthracycline derivative: DT, drug therapy
 taxane derivative: DT, drug therapy

trastuzumab: CB, drug combination
trastuzumab: DT, drug therapy
trastuzumab: PD, pharmacology
pyrimidine derivative: AE, adverse drug reaction
pyrimidine derivative: CB, drug combination
pyrimidine derivative: CM, drug comparison
pyrimidine derivative: DO, drug dose
pyrimidine derivative: IT, drug interaction
pyrimidine derivative: DT, drug therapy
pyrimidine derivative: PD, pharmacology
antineoplastic antimetabolite: AE, adverse drug reaction
antineoplastic antimetabolite: CB, drug combination
antineoplastic antimetabolite: CM, drug comparison
antineoplastic antimetabolite: DO, drug dose
antineoplastic antimetabolite: IT, drug interaction
antineoplastic antimetabolite: DT, drug therapy
antineoplastic antimetabolite: PD, pharmacology
docetaxel: CB, drug combination
docetaxel: DT, drug therapy
navelbine: CB, drug combination
navelbine: DT, drug therapy

=>